MULTIVALENT LIGAND-LIPID CONSTRUCTS
20170320914 · 2017-11-09
Inventors
- Nicolai Vladimirovich Bovin (Moscow, RU)
- Stephen Micheal Henry (Auckland, NZ)
- Elena Korchagina (Moscow, RU)
- Igor Leonidovich Rodionov (Moscow Region, RU)
- Alexander Borisovich Tuzikov (Moscow, RU)
Cpc classification
A61K31/7004
HUMAN NECESSITIES
A61K47/555
HUMAN NECESSITIES
C07K9/00
CHEMISTRY; METALLURGY
A61K31/702
HUMAN NECESSITIES
A61K31/685
HUMAN NECESSITIES
A61P35/00
HUMAN NECESSITIES
International classification
Abstract
Water dispersible, multivalent ligand-lipid constructs that spontaneously and stably incorporate into membranes are disclosed.
Claims
1-14. (canceled)
15. A construct of the structure: ##STR00035## where F is a ligand, L is a conjugated phosphatidylethanolamide and S is a tetraantennary spacer of the structure: ##STR00036## where m is the integer 1, 2 or 3 and R is of the structure: ##STR00037## where M is a monovalent cation or substituent, n is the integer 2, 3, 4, 5, 6 or 7, and * is the point of attachment of F or L.
16. The construct of claim 15 where M is H.
17. The construct of claim 16 where L is a conjugated phosphatidylethanolamide of the structure: ##STR00038## where p is the integer 3, 4 or 5, W.sup.1 and W.sup.2 are independently selected from C.sub.16-20-alkyl or mono- or di-unsaturated C.sub.16-20-alkenyl groups and * is the point of attachment of S.
18. The construct of claim 17 where the multivalent ligand-lipid construct comprises the partial structure: ##STR00039##
19. The construct of claim 18 where F is an aminoalkylglycoside and the multivalent ligand-lipid construct is of the structure: ##STR00040## where Glyc is a glycan and q and r are integers independently selected from 1, 2, 3 and 4.
20. The construct of claim 19 where Glyc is a glycan selected from the group consisting of the group of mono-, di-, tri- and oligosaccharides: (Neu5Acα6Galβ4GlcNAcβ2Manα).sub.23,6Manβ4GlcNAcβ4GlcNAcβ (YDS); Fucα2Galβ (H.sub.di); Fucα2Galβ3(Fucα4)GlcNAcβ (Le.sup.b); Fucα2Galβ3GlcNAcβ3Galβ4Glcβ4Glcβ (LNFP I); Fucα2Galβ4(Fucα3)GlcNAcβ (Le.sup.y); Fucα2Gal4GlcNAcβ (H2); Galα; Galβ1-3(Fucα1-3)GlcNAc;Galβ1-3(Fucα1-4)GlcNAcβ1-4GlcNAc;Galβ1-3GlcNAcβ1-4GlcNAc;Galβ1-3GlcNAc;Galβ1-4(Fucα1-3)GlcNAcβ1-4GlcNAc;Galβ1-4(Fucα1-3)GlcNAc;Galβ1-4GlcNAcβ1-4GlcNAc;Galβ1-4GlcNAc;Galα3(Fucα2)Galβ (B.sub.tri); Galα3(Fucα2)Galα3(Fucα4)GlcNAcβ (Ble.sup.b); Galα3(Fucα2)Galβ3GalNAcα (B3); Galα3(Fucα2)Galβ3GalNAcβ3 (B4); Galα3(Fucα2)Galβ3GlcNAcβ (B1); Galα3(Fucα2)Gal4(Fucα3)GlcNAcβ (Ble.sup.y); Galα3(Fucα2)Galβ4GlcNAcβ (B2); Galα3Galβ4GlcNAcβ (Galili); Galα4Galβ4GlcNAcβ (P.sub.1); Galα4Galβ4Glcβ (Gb3 (P.sup.k)); Galα4GlcNAcβ (α-LN); GalNAcα3(Fucα2)Galβ (A.sub.tri); GalNAcα3(Fucα2)Galβ3(Fucα4)GlcNAcβ (ALe.sup.b); GalNAcα3(Fucα2)Gaβ3GalNAcα (A3); GalNAcα3(Fucα2)Gaβ3GalNAcβ (A4); GalNAcα3(Fucα2)Galβ3GlcNAcβ (A1); GalNAcα3(Fucα2)Galβ4(Fucα3)GlcNAcβ (ALe.sup.y); GalNAcα3(Fucα2)Galβ4GlcNAcβ (A2); GalNAcα3GalNAcβ (Fs2); GalNAcα3GalNAcβ3Galα4Galβ4Glcβ (Fs5); GalNAcα3Galβ (A.sub.di); GalNAcα3Galβ4GlcNAcβ;GalNAcβ; GalNAcβ3Galα4Galβ4Glcβ (P); GalNH.sub.2α3(Fucα2)Galβ (AcqB); Galβ; Galβ3(Fucα4)GlcNAcβ (Le.sup.a); Galβ3GalNAcα (TF); Galβ3GalNAcβ4Galβ4Glcβ (GA1); Galβ4(Fucα3)GlcNAcβ (Le.sup.x); Galβ4GlcNAcβ3Galβ4GlcNAcβ (i(LN.sub.2)); Galβ4GlcNAcβ3Galβ4Glcβ (LNnT); Galβ4Glcβ (Lac); GlcAβ3[GlcNAcβ4GlcAβ3].sub.nGlcNAc-aminoalditol (hyaluronate); Manα6(Manα3)Manβ (Man.sub.3); Neu5Acα3Galβ4GlcNAcβ (Neu5Ac3′LN); Neu5Acα3Galβ4Glcβ (Neu5Ac3′Lac); Neu5Acα6GalNAcαβ (SiaTn); Neu5Acα6Galβ4GlcNAcβ (Neu5Ac6′LN); Neu5Gcα3Galβ4GlcNAcβ (Neu5Gc3′LN); SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAβ2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3G alβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-4Gal; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-4GlcNAc; SAα2-3Galβ1-3(Fucα1-4)GlcNAc; SAα2-3Gal1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAc; SAα2-3Galβ1-3GlcNAcβ1-4GlcNAc; SAα2-3Galβ1-3GlcNAc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Gal β1-4Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1- 4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-4Gal; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-4GlcNAc; SAα2-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-3Galβ1-4Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-3Galβ1-4GlcNAcβ1-4GlcNAc; SAα2-3Galβ1-4GlcNAc; SAα2-6Galβ1-3(Fucα1-4(GlcNAc; SAα2-6Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Gaβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-6Gaβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Gaβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6G alβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4Glc; SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-4GlcNAcβ1-3Gaβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-6Galβ1-4GlcNAcβ1-4GlcNAc; SAα2-6Galβ1-4GlcNAc; SAα2-3Gaβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAc and SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAc.
21. The construct of claim 20 where Glyc is a glycan selected from the group consisting of the group of mono-, di-, tri- and oligosaccharides: (Neu5Acα6Galβ4GlcNAcβ2Manα).sub.23,6Manβ4GlcNAcβ4GlcNAcβ (YDS); Fucα2Galβ (H.sub.di); Fucα2Galβ3(Fucα4)GlcNAcβ (Le.sup.b); Fucα2Galβ3GlcNAcβ3Galβ4Glcβ (LN FP I); Fucα2Galβ4(Fucα3)GlcNAcβ (Le.sup.y); Fucα2Galβ4GlcNAcβ (H2); Galα; Galα3(Fucα2)Galβ (B.sub.tri); Galα3(Fucα2)Galβ3(Fucα4)GlcNAcβ (Ble.sup.b); Galα3(Fucα2)Galβ3GalNAcα (B3); Galα3(Fucα2)Galβ3GalNAcβ (B4); Galα3(Fucα2)Galβ3GlcNAcβ (B1); Galα3(Fucα2)Galβ4(Fucα3)GlcNAcβ (Ble.sup.y); Galα3(Fucα2)Galβ4GlcNAcβ (B2); Galα3Galβ4GlcNAcβ (Galili); Galα4Galβ4GlcNAcβ (P.sub.1); Galα4Galβ4Glcβ (Gb3 (P.sup.k)); Galα4GlcNAcβ (α-LN); GalNAcα3(Fucα2)Galβ (A.sub.tri); GalNAcα3(Fucα2)Galβ3(Fucα4)GlcNAcβ (ALe.sup.b); GalNAcα3(Fucα2)Galβ3GalNAcα (A3); GalNAcα3(Fucα2)Galβ3GalNAcβ (A4); GalNAcα3(Fucα2)Galβ3GlcNAcβ (A1); GalNAcα3(Fucα2)Galβ4(Fucα3)GlcNAcβ (ALe.sup.y); GalNAcα3(Fucα2)Galβ4GlcNAcβ (A2); GalNAcα3GalNAcβ (Fs2); GalNAcα3GalNAcβ3Galα4Galβ4Glcβ (Fs5); GalNAcα3Galβ (A.sub.di); GalNAcα3Galβ4GlcNAcβ; GalNAcβ;GalNAcβ3Galα4Galβ4Glcβ (P); GalNH.sub.2α3(Fucα2)Galβ (AcqB); Galβ; Galβ3(Fucα4)GlcNAcβ (Le.sup.a); Galβ3GalNAcα (TF); Galβ3GalNAcβ4Galβ4Glcβ (GA1); Galβ4(Fucα3)GlcNAcβ (Le.sup.x); Galβ4GlcNAcβ3Galβ4GlcNAcβ (i(LN.sub.2)); Galβ4GlcNAcβ3Galβ4Glcβ (LNnT); Galβ4Glcβ (Lac); GlcAβ3[GlcNAcβ4GlcAβ3].sub.nGlcNAc-aminoalditol (hyaluronate); Manα6(Manα3)Manβ (Man.sub.3); Neu5Acα3Galβ4GlcNAcβ (Neu5Ac3′LN); Neu5Acα3Galβ4Glcβ (Neu5Ac3′Lac); Neu5Acα6GalNAcαβ (SiaTn); Neu5Acα6Galβ4GlcNAcβ (Neu5Ac6′LN) and Neu5Gcα3Galβ4GlcNAcβ (Neu5Gc3′LN).
22. The construct of claim 21 where Glyc is a glycan selected from: Galα3Galβ4GlcNAcβ (Galili) and GalNAcα3Galβ4GlcNAcβ.
23. The construct of claim 18 where F is an oligopeptide comprising an N-maleoyl-β-alanine conjugated Cys residue and the multivalent ligand-lipid construct is of the structure: ##STR00041## where Xaa is an amino acid residue and i and j are independently either zero or integers the sum of which is in the range 5 to 30 inclusive.
24. The construct of claim 23 where i is an integer in the range 5 to 30 inclusive and j is zero.
25. The construct of claim 24 where i is the integer 13 and j is zero.
26. The construct of claim 25 where the oligopeptide is the peptide of SEQ ID NO: 01.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0031]
[0032]
DESCRIPTION OF EMBODIMENTS
[0033] The multivalent presentation of ligands is particularly advantageous where the ligands are glycans. The affinities of glycan-binding proteins (GBPs) for glycan ligands in the monovalent state are generally very low. The multivalent presentation of glycan ligands permits GBPs such as antibodies to bind with increased avidity. In general, the multivalent presentation of glycan ligands amplifies differences in specificity of binding of GBPs relative to the low intrinsic affinities of GBPs for their glycan ligands.
[0034] As a result the presence of GBPS in human sera may be detected using simple agglutination or cell lysis assays.
Chemistry
[0035] Preparation of (Boc-Gly.sub.2-HNCH.sub.2) .sub.4C (3) (step i of SCHEME I)
[0036] Tetraamine (H.sub.2N—CH.sub.2).sub.4C (1) was synthesized according the method disclosed in the publication of Litherland et al (1938). To a stirred solution of the tetraamine 1 (500 rag, 1.52 mmol) in a mixture of 1M aqueous NaHCO.sub.3 (18.2 ml) and i-PrOH (9 ml), Boc-GlyGlyNos (2) (4012 mg, 12.18 mmol) was added (CO.sub.2 evolution, foaming). The reaction mixture was stirred for 30 min, then 6 ml of 1M aqueous NaHCO.sub.3 was added and the mixture stirred overnight. Precipitate of (Boc-Gly.sub.2-HNCH.sub.2) (3) was filtered, washed thoroughly with methanol/water mixture (1:1, 20 ml) and dried in vacuum. Yield 1470 mq (98%), white solid.
[0037] .sup.1H NMR (500 MHz, [D.sub.6] DMSO, 30° C.) δ, ppm: 8.491 (t, J=5.6 Hz, 1H; NHCO),7.784 (t, J=6.6 Hz, 1H; C—CH.sub.2—NHCO), 6.858 (t, J=6 Hz, 1H; NHCOO), 3.696 (d, J=5.6 Hz, 2H; COCH.sub.2NH), 3.675 (d, J=6 Hz, 2H; COCH.sub.2NHOO), 2.685 (d, J=6.6 Hz, 2H; C—CH.sub.2NH), 1.375 (s, 9H; C(CH.sub.3).sub.3.
Preparation of (CF.sub.3COOH.Math.H-Gly.sub.2-NHCH.sub.2) .sub.4C (4) (step ii of SCHEME I)
[0038] The (Boc-Glyn.sub.2-HNCH.sub.2).sub.4C (3) (1450 mg, 1.466 mmol) was dissolved in CF.sub.3COOH (5 ml) and the solution was kept for 2 h at room temperature. Trifluoroacetic acid was removed under vacuum and the residue was three times extracted with (CH.sub.3CH.sub.2).sub.2O (slight agitation with 30 ml of (CH.sub.3CH.sub.2).sub.2O for 30 min., followed by decantation) to eliminate residual CF.sub.3COOH. Solid residue was dried under vacuum, dissolved in a minimum volume of water and passed through a Sephadex LH-20 column and elutd with water. Fractions, containing product 4, were combined, evaporated to c. 5 ml and freeze dried. Yield 1424 mg (93%), white solid. TIC: R.sub.f 0.5 (ethanol/conc. NH.sub.3; 2:1 (v/v)).
[0039] .sup.1H NMR (500 MHz, [D.sub.2] H.sub.2O, 30° C.) δ, ppm: 4.028 (s, 2H; COCH.sub.2NH), 3.972 (s, 2H; COCH.sub.2NH), 2.960 (s, 2H; C—CH.sub.2NH).
Preparation of {[2-(2-tert-butoxycarbonylamino-acetylamino)-acetyl]-methoxy-carbonylmethyl-amino}-acetic acid methyl ester (7) (step i of SCHEME II)
[0040] To a stirred solution of (methoxycarbonylmethyl-amino)-acetic acid methyl ester hydrochloride (5) (988 mg, 5 mmol) in DMF (15 ml) Boc-GlyGlyNos (2) (3293 mg, 10 mmol) and (CH.sub.3CH.sub.2) .sub.3N (3475 μL, 25 mmol) were added. The mixture was stirred overnight at room temperature and then diluted with o-xylene (70 ml) and evaporated. Flash column chromatography on silica gel (packed in toluene, and eluted with ethyl acetate) resulted in a crude product. The crude product was dissolved in chloroform and washed sequentially with water, 0.5 M NaHCO.sub.3 and saturated KCl. The chloroform extract was evaporated and the product purified on a silica gel column (packed in chloroform and eluted with 15:1 (v/v) chloroform/methanol). Evaporation of the fractions and drying under vacuum of the residue provided a colourless thick syrup of product 7. Yield 1785 mg, (95%). TLC: R.sub.f=0.49 (7:1 (v/v) chloroform/methanol).
[0041] .sup.1H NMR (500 MHz, [D.sub.6] DMSO, 30° C.) δ, ppm: 7.826 (t, J=5.1 Hz, 1H; NHCO), 6.979 (t, J=5.9 Hz, 1H; NHCOO), 4.348 and 4.095 (s, 2 H; NCH.sub.2COO), 3.969 (d, J=5.1 Hz, 2 H; COCH.sub.2NH), 3.689 and 3.621 (s, 3 H; OCH.sub.3), 3.559 (d, J=5.9 Hz, 2 H; COCH.sub.2NHCOO), 1.380 (s, 9 H; C(CH.sub.3).sub.3).
Preparation of {[2-(2-tert-butoxycarbonylamino-acetylamino) acetyl]-methoxycarbonyl-methyl-amino}-acetic acid (8) (step ii of SCHEME II)
[0042] To a stirred solution of 7 (1760 mg, 4.69 mmol) in methanol (25 ml) 0.2 M aqueous NaOH (23.5 ml) was added and the solution kept for 5 min at room temperature. The solution was then acidified with acetic acid (0.6 ml) and evaporated to dryness. Column chromatography of the residue on silica gel (packed in ethyl acetate and eluted with 2:3:1 (v/v/v) i-PrOH/ethyl acetate/water) resulted in a recovered 7 (63 mg, 3.4%) and target compound 8 (1320 mg). The intermediate product was then dissolved in methanol/water/pyridine mixture (20:10:1, 30 ml) and passed through an ion exchange column (Dowex 50×4-400, pyridine form, 5 ml) to remove residual sodium cations. The column was then washed with the same solvent mixture, the eluant evaporated, the residue dissolved in chloroform/benzene mixture (1:1, 50 ml) and then evaporated and dried under vacuum. Yield of product 8 was 1250 mg (74%), white solid. TLC: R.sub.f 0.47 (4:3:1 (v/v/v) i-PrOH/ethyl acetate/water).
[0043] .sup.1H NMR (500 MHz, [D.sub.6] DMSO, 30° C.), mixture of cis- and trans-conformers of N-carboxymethylglycine unit c.3:1. Major conformer; δ, ppm: 7.717 (t, J=5 Hz, 1 H; NHCO), 7.024 (t, J=5.9 Hz, 1 H; NHCOO), 4.051 (s, 2 H; NCH.sub.2COOCH.sub.3), 3.928 (d, J=5 Hz, 2 H; COCH.sub.2NH), 3.786 (s, 2 H; NCH.sub.2COOH), 3.616 (s, 3 H; OCH.sub.3), 3.563 (d, J=5.9 Hz, 2 H; COCH.sub.2NHCOO), 1.381 (s, 9 H; C(CH.sub.3).sub.3) ppm; minor conformer, δ=7.766 (t, J=5 Hz, 1 H; NHCO), 7.015 (t, J=5.9 Hz, 1 H; NHCOO), 4.288 (s, 2 H; NCH.sub.2COOCH.sub.3), 3.928 (d, J=5 Hz, 2 H; COCH.sub.2NH), 3.858 (s, 2 H; NCH.sub.2COOH), 3.676 (s, 3 H; OCH.sub.3), 3.563 (d, J=5.9 Hz, 2 H; COCH.sub.2NHCOO), 1.381 (s, 9 H; C(CH.sub.3).sub.3).
##STR00011##
Preparation of {[2-(2-tert-Butoxycarbonylamino-acetylamino)-acetyl]-methoxycarbonylmethyl-amino}-acetic acid N-oxysuccinimide ester (Boc-Gly.sub.2(MCMGly) Nos) (9) (step iii of SCHEME III)
[0044] To an ice-cooled stirred solution of 8 (1200 mg, 3.32 mmol) and N-hydroxysuccinimide (420 mg, 3.65 mmol) in DMF (10 ml) was added N,N-dicyclohexylcarbodiimide (754 mg, 3.65 mmol). The mixture was stirred at 0° C. for 30 min, then for 2 hours at room temperature. The precipitate of N,N-dicyclohexylurea was filtered off, washed with DMF (5 ml), and filtrates evaporated to a minimal volume. The residue was then agitated with (CH.sub.3CH.sub.2).sub.2O (50 ml) for 1 hour and an ether extract removed by decantation. The residue was dried under vacuum providing the ester 9 (1400 mg, 92%) as a white foam. TLC: R.sub.f 0.71 (40:1 (v/v) acetone/acetic acid).
[0045] .sup.1H NMR (500 MHz, [D.sub.6] DMSO, 30° C.), mixture of cis- and trans-conformers of N-carboxymethylglycine unit c. 3:2.
[0046] Major conformer; δ, ppm: 7.896 (t, J=5.1 Hz, 1 H; NHCO), 6.972 (t, J=5.9 Hz, 1H; NHCOO), 4.533 (s, 2 H; NCH.sub.2COON), 4.399 (s, 2 H; NCH.sub.2COOCH.sub.3), 3.997 (d,
##STR00012##
J=5.1 Hz, 2 H; COCH.sub.2NH), 3.695 (s, 3 H; OCH.sub.3), 3.566 (d, J=5.9 Hz, 2 H; COCH.sub.2NHCOO), 1.380 (s, 9 H; C(CH.sub.3).sub.3).
[0047] Minor conformer; δ, ppm: 7.662 (t, J=5.1 Hz, 1 H; NHCO), 6.963 (t, J=5.9 Hz, 1H; NHCOO), 4.924 (s, 2 H; NCH.sub.2COON), 4.133 (s, 2 H; NCH.sub.2COOCH.sub.3), 4.034 (d, J=5.1 Hz, 2 H; COCH.sub.2NH), 3.632 (s, 3 H; OCH.sub.3), 3.572 (d, J=5.9 Hz, 2 H; COCH.sub.2NHCOO), 1.380 (s, 9 H; C(CH.sub.3).sub.3).
[0048] The ester 9 (1380 mg) was dissolved in DMSO to provide a volume of 6 ml and used as a 0.5 M solution (stored at −18° C.).
Preparation of {Boc-[Gly.sub.2 (MCMGly)] Gly.sub.2-NHCH.sub.2}.sub.4C (10) (step i of SCHEME III)
[0049] To a stirred solution of (CF.sub.3COOH.Math.H-Gly.sub.2-HNCH.sub.2).sub.4C (4) (277 mg, 0.265 mmol) in DMSO (2 ml) the ester 9 (1.591 mmol, 3.18 ml of 0.5 M solution in DMSO) and (CH.sub.3CH.sub.2).sub.3N (295 μL, 2.121 mmol) were added. The mixture was stirred overnight at room temperature, acidified with 150 μL AcOH and solvent removed under vacuum (freeze drying). The residue was extracted three times with (CH.sub.3CH.sub.2).sub.2O (slight agitation with 20 ml of (CH.sub.3CH.sub.2).sub.2O for 30 min followed by decantation). The solid residue was dissolved in a minimal volume of acetone and fractionated on silica gel column (packed in acetone and eluted with acetone, 20:2:1 (v/v/v) acetone/methanol/water and. 15:2:1 (v/v/v) acetone/methanol/water). Selected fractions were evaporated and the residue was dried under vacuum. The yield of pure {Boc-[Gly.sub.2(MCMGly)]Gly.sub.2NHCH.sub.2}.sub.4C (10) was 351 mg (68%), white solid. TLC: R.sub.f 0.38 (15:2:1 (v/v/v) acetone/methanol/water).
[0050] .sup.1H NMR (500 MHz, [D.sub.6] DMSO, 30° C.), mixture of cis- and trans-conformers of N-carboxymethylglycine unit in chain c. 3:2.
[0051] Major conformer; δ, ppm: 8.593 (t, J=5 Hz, 1 H; NHCO), 8.335 (t, J=5.4 Hz, 1 H; NHCO), 7.821 (t, J=6.4 Hz, 1 H; C—CH.sub.2 —NHCO), 7.786 (t, J=5.1 Hz, 1 H; NHCO), 6.993 (t, J=6 Hz, 1 H; NHCOO), 4.139 (s, 2 H; NCH.sub.2CO), 4.074 (s, 2 H; NCH.sub.2COO(CH.sub.3)), 3.985 (d, J=5 Hz, 2 H; COCH.sub.2NH), 3.887 (d, J=5.4 Hz, 2 H; COCH.sub.2NH), 3.726 (d, J=5.1 Hz, 2 H; COCH.sub.2NH), 3.634 (s, 3 H; OCH.sub.3), 3.567 (d, J=6 Hz, 2 H; COCH.sub.2NHCOO), 2.686 (broad. d, J=6.4 Hz, 2 H; C—CH.sub.2NH), 1.379 (s, 9 H; C(CH.sub.3).sub.3).
[0052] Minor conformer; δ, ppm: 8.511 (t, J=5 Hz, 1 H; NHCO), 8.158 (t, J=5.4 Hz, 1 H; NHCO), 7.821 (t, J=6.4 Hz, 1 H; C—CH.sub.2NHCO), 7.786 (t, J=5.1 Hz, 1 H; NHCO), 6.993 (t, J=6 Hz, 1 H; NHCOO), 4.292 (s, 2 H; NCH.sub.2CO), 3.998 (s, 2 H; NCH.sub.2COOCH.sub.3), 3.954 (d, J=5 Hz, 2 H; COCH.sub.2NH), 3.826 (d, J=5.4 Hz, 2 H; COCH.sub.2NH), 3.715 (d, J=5.1 Hz, 2 H; COCH.sub.2NH), 3.692 (s, 3 H; OCH.sub.3), 3.567 (d, J=6 Hz, 2 H; COCH.sub.2NHCOO), 2.686 (broad. d, J=6.4 Hz, 2 H; C—CH.sub.2NH), 1.379 (s, 9 H; C(CH.sub.3).sub.3).
Preparation of {CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly)]Gly.sub.2-NHCH.sub.2}.sub.4C (11) (step ii of SCHEME III )
[0053] The {Boc-[Gly.sub.2(MCMGly)]Gly.sub.2-NHCH.sub.2}.sub.4C (10) (330 mg, 0.168 mmol) was dissolved in CF.sub.3COOH (2 ml) and the solution was kept for 40 min at room temperature. Trifluoroacetic acid was evaporated under vacuum, the residue extracted three times with (CH.sub.3CH.sub.2).sub.2O (slight agitation with 20 ml of (CH.sub.3CH.sub.2).sub.2O for 30 min followed by decantation) to eliminate residual CF.sub.3COOH, and then dried under vacuum. The yield of {CF.sub.3COOH.Math.H-[Gly.sub.2(MGMGly)]Gly.sub.2-NHCH.sub.2}.sub.4C (11) was 337 mg (99%), white solid.
[0054] .sup.1H NMR (500 MHz, [D.sub.2]H.sub.2O, 30° C.), mixture of cis- and trans-conformers of N-carboxymethylglycine unit in chain c. 11:10.
[0055] Major conformer; δ, ppm: 4.370 (s, 2 H; NCH.sub.2CO), 4.265 (s, 2 H; NCH2COOCH.sub.3), 4.215 (s, 2 H; COCH.sub.2NH), 4.138 (s, 2 H; COCH.sub.2NH), 3.968 (s, 2 H; COCH.sub.2NH), 3.919 (s, 2 H; COCH.sub.2NH.sub.2.sup.+), 3.775 (s, 3 H; OCH.sub.3), 2.914 (s, 2 H; C—CH.sub.2NH).
[0056] Minor conformer; δ, ppm: 4.431 (s, 2 H NCH.sub.2CO), 4.241 (s, 2 H; NCH.sub.2COOCH.sub.3), 4.239 (s, 2 H; COCH.sub.2NH), 4.074. (s, 2 H; COCH.sub.2NH), 3.960 (s, 2 H; COCH.sub.2NH), 3.919 (s, 2 H; COCH.sub.2NH.sub.2.sup.+), 3.829 (s, 3 H; OCH.sub.3), 2.914 (s, 2 H; C—CH.sub.2NH).
Preparation of {CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly) ].sub.2Gly.sub.2-NHCH.sub.2}.sub.4C (13) (steps i and ii of SCHEME IV)
[0057] To a stirred solution of (CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly)]Gly.sub.2-HNCH.sub.2).sub.4C (11) (272 mg, 0.135 mmol) in DMSO (2 ml) the ester 9 (0.809 mmol, 1.62 ml of 0.5 M solution in DMSO) and (CH.sub.3CH.sub.2).sub.3N (112 μL, 0.809 mmol) were added. The mixture was stirred overnight at room temperature, acidified with 70 μL AcOH and solvent removed under vacuum (freeze drying). The residue was extracted three times with (CH.sub.3CH.sub.2).sub.2O (slight agitation with 15 ml of (CH.sub.3CH.sub.2).sub.2O for 30 min followed by decantation). Solid residue was dissolved in a minimal volume of 7:1 (v/v) acetone/methanol mixture and fractionated on a silica gel column (packed in acetone and eluted with 7:1 (v/v) acetone/methanol, 10:2:1 (v/v/v), 9:2:1 (v/v/v), 8:2:1 (v/v/v) acetone/methanol/water). Selected fractions were evaporated. and the residue was dried in vacuum. The yield of pure {Boc-[Gly.sub.2(MCMGly)].sub.2Gly.sub.2-NHCH.sub.2}.sub.4C (12) was 279 mg (71%), white solid. TLC: R.sub.f 0.42 (8:2:1 (v/v/v) acetone/methanol/water).
[0058] .sup.1H NMR (500 MHz, [D.sub.6]DMSO, 30° C.), mixture of conformers by two N-carboxymethyl-glycine units per chain, δ, ppm: 8.604, 8.519, 8.397, 8.388, 8.346, 8.211, 8.200, 8.167, 8.034, 8.024, 7.925, 7.912, 7.819 and 7.773 (t, 6 H; 6 NHCO), 6.992 (t, J=5.9 Hz, 1 H; NHCOO), 4.302-3.723 (18 H; 2 NCH.sub.2CO, 2 NCH.sub.2COOCH.sub.3, 5 COCH.sub.2NH), 3.692, 3.689 and 3.632 (s, 6 H; 2 OCH.sub.3), 3.566 (d, j=5.9 Hz, 2 H; COCH.sub.2NHCOO), 2.686 (broad. d, 2 H; C—CH.sub.2NH), 1.380 (s, 9 H; C(CH.sub.3).sub.3).
[0059] The {Boc-[Gly.sub.2(MCMGly)].sub.2Gly.sub.2-NHCH.sub.2}.sub.4C (12) (269 mg, 91.65 μmol) was dissolved in CF.sub.3COOH (2 ml) and the solution was kept for 40 min at room temperature. Trifluoroacetic acid was evaporated under vacuum, the residue extracted three times with (CH.sub.3CH.sub.2).sub.2O (slight agitation with 15 ml of (CH.sub.3CH.sub.2).sub.2O for 30 min followed by decantation) to remove residual CF.sub.3COOH, and then dried under vacuum. The yield of {CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly)].sub.2Gly.sub.2-NHCH.sub.2}.sub.4C (13) was 270 mg (98%), white solid.
##STR00013##
[0060] .sup.1H NMR (500 MHz, [D.sub.2]H.sub.2O, 30° C.), mixture of conformers by two N-carboxymethyl-glycine units per chain, δ, ppm: 4.441-3.963 (singlets, 18 H; 2 NCH.sub.2CO, 2 NCH.sub.2COOCH.sub.3, 5 COCH.sub.2NH), 3.920 (s, 2 H; COCH.sub.2NH.sub.2.sup.+), 3.833, 3.824, 3.780 and 3.773 (s, 6 H; 2 OCH.sub.3), 2.918 (s, 2 H; C—CH.sub.2NH).
Preparation of {CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly)].sub.3Gly.sub.2-NHCH.sub.2}.sub.4C (15) (steps iii and iv of SCHEME IV)
[0061] To a stirred solution of (CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly)].sub.2Gly.sub.2-HNCH2).sub.4C (13) (175 mg, 58.5 μmol) in DMSO (2 ml) the ester 9 (0.351 mmol, 0.702 ml of 0.5 M solution in DMSO) and (CH.sub.3CH.sub.2) .sub.3N (49 μL, 0.351 mmol) were added. The mixture was stirred overnight at room temperature, acidified with 30 μL AcOH and solvent removed under vacuum (freeze drying). The residue was dissolved in a minimal volume of a mixture of 1:1 (v/v) acetonitrile/water and fractionated on a Sephadex LH-20 column (eluted with 1:1 (v/v) acetonitrile/water). Selected fractions were evaporated and the residue was dried in vacuum. The yield of pure {Boc-[Gly.sub.2(MCMGly)].sub.3Gly.sub.2-NHCH.sub.2}.sub.4C (14) was 279 mg (71%), white solid. TLC: R.sub.f 0.42 (8:2:1 (v/v/v) acetone/methanol/water). Fractions containing {Boc-[Gly.sub.2(MCMGly)].sub.3Gly.sub.2-NHCH.sub.2}.sub.4C (14) were combined, evaporated to c, 2 ml volume and freeze dried. The initial yield was 215 mg (94%). Additional purification on a silica gel column (packed in acetonitrile and eluted with 4:5:2 (v/v/v) i-PrOH/acetonitrile/water) resulted in 169 mg of Boc-[Gly.sub.2(MCMGly)].sub.3Gly.sub.2-NHCH.sub.2}.sub.4C (yield 74%, white solid). TLC: R.sub.f 0.45 (4:5:2 (v/v/v) i-PrOH/acetonitrile/water).
[0062] .sup.1H NMR (500 MHz, [D.sub.6]DMSO, 30° C.), mixture of conformers by three N-carboxymethyl-glycine units per chain, δ, ppm: 8.594-7.772 (triplets, together 8 H; 8 NHCO), 6.989 (t, J=5.6 Hz, 1 H; NHCOO), 4.303-3.722 (26 H; 3 NCH.sub.2CO, 3 NCH.sub.2COOOH.sub.3, 7 COCH.sub.2NH), 3.692 and 3.632 (s, 9 H; 3 OCH.sub.3), 3.565 (d, J=5.6 Hz, 2 H; COCH.sub.2NHCOO), 2.687 (broad. d, 2 H; C—CH.sub.2NH), 1.380 (s, 9 H; C (CH.sub.3).sub.3).
[0063] The {Boc-[Gly.sub.2(MCMGly)].sub.3Gly.sub.2-NHCH.sub.2}.sub.4C (146 mg, 37.36 μmol) (14) was dissolved in CF.sub.3COOH (1 ml) and the solution was kept for 40 min at room temperature. Trifluoroacetic acid was evaporated under vacuum, the residue extracted three times with (CH.sub.3CH.sub.2).sub.2O (slight agitation with 10 ml of (CH.sub.3CH.sub.2).sub.2O for 30 min followed by decantation) to remove residual CF.sub.3COOH, and then dried under vacuum. The yield of {CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly)].sub.3Gly.sub.2-NHCH.sub.2}.sub.4C (15) was 147 mg (99%), white solid.
[0064] .sup.1H NMR (500 MHz, [D.sub.2]H.sub.2O, 30° C.), mixture of conformers by three N-carboxymethyl-glycine units per chain, δ, ppm: 4.446-3.964 (singlets, 26 H; 3 NCH.sub.2CO, 3 NCH.sub.2COOCH.sub.3, 7 COCH.sub.2NH), 3.924 (s, 2 H; COCH.sub.2NH.sub.2.sup.+),3.836, 3.828, 3.824, 3.783, 3.778 and 3.773 (s, 9 H; 3 OCH.sub.3), 2.919 (s, 2 H; C—CH.sub.2NH).
Preparation of {CF.sub.3OOH.Math.H-[Gl y.sub.2 (MCMGly) ].sub.4Gly.sub.2-NHCH.sub.2}.sub.4C (17) (steps v and vi of SCHEME IV)
[0065] To a stirred solution of (CF.sub.3COOH.Math.H-Gly.sub.2(MCMGly)].sub.3-HNCH.sub.2).sub.4C (15) (68 mg, 17.16 μmol) in DMSO (1 ml) the ester 9 (0.137 mmol, 0.275 ml of 0.5 M solution in DMSO) and (CH.sub.3CH.sub.2).sub.3N (14.3 μL, 0.103 mmol) were added. The mixture was stirred overnight at room temperature, acidified with 100 μL, AcOH and solvent removed under vacuum (freeze drying). The residue was dissolved in a minimal volume of a mixture of 1:1 (v/v) acetonitrile/water (0.25% AcOH) and fractionated on a Sephadex LH-20 column (eluted with 1:1 (v/v) acetonitrile/water (0.25% AcOH)). Fractions containing {Boc-[Gly.sub.2(MCMGly)].sub.4Gly.sub.2-NHCH.sub.2}.sub.4C (16) were combined, evaporated to c, 2 ml volume and freeze dried. The yield was 81 mg (96%), white solid. TLC: R.sub.f 0.24 (4:5:2 (v/v/v) i-PrOH/acetonitrile/water).
##STR00014##
[0066] .sup.1H NMR (500 MHz, [D.sub.6]DMSO, 30° C.), mixture of conformers by four N-carboxymethyl-glycine units per chain, δ, ppm: 8.590-7.773 (triplets, 10 H; 10 NHCO), 6.989 (t, J=5.6 Hz, 1 H; NHCOO), 4.303-3.722 (34 H; 4 NCHCO, 4 NCH.sub.2COOCH.sub.3, 9 COCH.sub.2NH), 3.691 and 3.631 (s, 12 H; 4 OCH.sub.3), 3.565 (d, J=5.6 Hz, 2 H; COCH.sub.2NHCOO), 2.684 (broad. d, 2 H; C—CH.sub.2NH), 1.379 (s, 9 H; C(CH.sub.3).sub.3).
[0067] The {Boc-[Gly.sub.2(MCMGly)].sub.4Gly.sub.2-NHCH.sub.2}.sub.4C (16) (74 mg, 15.16 μmol) was dissolved in CF.sub.3COOH (1 ml) and the solution was kept for 40 min at room temperature. Trifluoroacetic acid was evaporated under vacuum, the residue extracted three times with (CH.sub.3CH.sub.2).sub.2O (slight agitation with 10 ml of (CH.sub.3,CH.sub.2).sub.2O for 30 min followed by decantation) to remove residual CF.sub.3COOH, and then dried under vacuum. The yield of {CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly)].sub.4Gly.sub.2-NHCH.sub.2}.sub.4C (17) was 72 mg (96%), white solid.
[0068] .sup.1H NMR (500 MHz, [D.sub.2]H.sub.2O, 30 ° C.), mixture of conformers by four N-carboxymethyl-glycine units per chain, δ, ppm: 4.446-3.964 (singlets, 34 H; 4 NCH.sub.2CO, 4 NCH.sub.2COOCH.sub.3, 9 COCH.sub.2NH), 3.925 (s, 2 H; COCH.sub.2NH.sub.2.sup.+), 3.836, 3.829, 3.827, 3.822, 3.783, 3.779, 3.777 and 3.772 (s, 12 H; 4 OCH.sub.3), 2.919 (s, 2 H; C—CH.sub.2NH).
Preparation of {CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly)].sub.5Gly.sub.2-NHCH.sub.2).sub.4C (19) (steps vii and viii of SCHEME IV)
[0069] To a stirred solution of (CF.sub.3COOH.Math.H-Gly.sub.2 (MCMGly)].sub.4-HNCH.sub.2}.sub.4C (17) (16.8 mg, 3.403 μmol) in DMSO (1 ml) the ester 9 (27.2 μmol, 63 μl of 0.5 M solution in DMSO) and (CH.sub.3CH.sub.2).sub.3N (3 μl , 21.6 μmol) were added. The mixture was stirred overnight at room temperature, acidified with 100 μL, AcOH and solvent removed under vacuum (freeze drying). The residue was dissolved in a minimal volume of a mixture of 1:1 (v/v) acetonitrile/water (0.25% AcOH) and fractionated on a Sephadex LH-20 column (eluted with 1:1 (v/v) acetonitrile/water (0.25% AcOH)). Fractions containing {Boc-[Gly.sub.2(MCMGly)].sub.5Gly.sub.2-NHCH.sub.2}.sub.4C (18) were combined, evaporated to c. 1 ml volume and freeze dried. The yield was 19 mg (95%), white solid. TLC: R.sub.f0.15 (4:3:2 (v/v/v) i-PrOH/acetonitrile/water).
[0070] .sup.1H NMR (500 MHz, [D.sub.6]DMSO, 30° C.), mixture of conformers by five N-carboxymethyl-glycine units per chain, δ, ppm: 8.595-7.772 (triplets, 12 H; 12 NHCO), 6.989 (t, J=5.6 Hz, 1 H; NHCOO), 4.303-3.723 (42 H; 5 NCH.sub.2CO, 5 NCH.sub.2COOCH.sub.3, 11 COCH.sub.2NH), 3.692 and 3.631 (s, 15 H; 5 OCH.sub.3), 3.565 (d, J=5.6 Hz, 2 H; COCHH.sub.2NHCOO), 2.686 (broad. d, 2 H; C—CH.sub.2NH), 1.380 (s, 9 H; C(CH.sub.3).sub.3).
[0071] The {Boc-[Gly.sub.2(MCMGly)].sub.5Gly.sub.2-NHCH.sub.2}.sub.4C (18) (19 mg, 3.25 μmol) was dissolved in CF.sub.3COOH (0.5 ml) and the solution was kept for 40 min at room temperature. Trifluoroacetic acid was evaporated under vacuum, the residue extracted three times with (CH.sub.3CH.sub.2).sub.2O (slight agitation with 5 ml of (CH.sub.3CH.sub.2).sub.2O for 30 min followed by decantation) to remove residual CF.sub.3COOH, and then dried under vacuum. Yield of {CF.sub.3COOH.Math.H-[Gly.sub.2(MCMGly)].sub.5Gly.sub.2-NHCH.sub.2}.sub.4C (19) was 20 mg (99%), white solid.
[0072] .sup.1H NMR (500 MHz, [D.sub.2]H.sub.2O, 30° C.), mixture of conformers by five N-carboxymethyl-glycine units per chain, δ, ppm: 4.446-3.965 (singlets, 42 H; 5 NCH.sub.2COOCH.sub.3, 11 COCH.sub.2NH), 3.924 (s, 2 H; COCH.sub.2NH.sub.2.sup.+), 3.835, 3.829, 3.827, 3.825, 3.823, 3.783, 3.779, 3.777 and 3.773 (s, 15 H; 5 OCH.sub.3), 2.919 (s, 2 H; C—CH.sub.2NH).
Preparation of [CF.sub.3COOH.Math.H-(Gly.sub.2CMGly).sub.5Gly.sub.2-NHCH.sub.2].sub.4C, Et.sub.3N-salt (20) (SCHEME IV)
[0073] To a solution of product 19 (463 mg, 0.07835 mmol) in water (25 mL), Et.sub.3N (523 μL, 3.761 mmol) was added and the solution kept for 18 h at r.t. After evaporation the residue was freeze-dried in vacuum. Yield of product 20 was 587 mg (98%), white solid. TLC: R.sub.f 0.39 (1:2:1 (v/v/v) CHCl.sub.3/MeOH/water).
[0074] .sup.1H NMR (600 MHz, [D.sub.2]H.sub.2O, 30° C.) δ, ppm: 4.309-3.919 (176 H; 20 NCH.sub.2CO, 20 NCH.sub.2COOH, 48 COCH.sub.2NH), 3.226 (q, 120 H, J=7.3 Hz; 60 NCH.sub.2CH.sub.3), 2.964 (broad. s, 8 H; 4 C—CH.sub.2NH), 1.305 (t, 180 H, J=7.3 Hz; 60 NCH.sub.2CH.sub.3). MALDI TOF mass-spectrum, M/Z: 5174, M+H; 5196, M+Na.
Preparation of activated 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DE-Ad-OSu) (23) (step i of SCHEME V)
[0075] To a solution of bis(N-hydroxysuccinimidyl) adipate (21) (70 mg, 205 μmol) in dry N,N-dimethylformamide (1.5 ml), 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine (22) (40 μmol) in chloroform (1.5 ml) was added, followed by triethylamine (7 μl). The mixture was kept for 2 h at room temperature, then neutralized with acetic acid and partially concentrated under vacuum. Column chromatography (Sephadex LH-20, 1:1 chloroform-methanol, 0.2% acetic acid) of the residue yielded the product 23 (37 mg, 95%) as a colorless syrup.
[0076] .sup.1H NMR (CDCl.sub.3/CD.sub.3OD, 2:1) 5.5 (m, 4 H, 2×(—CH=CH-), 5.39 (m, 1 H, —OCH.sub.2-CHO-CH.sub.2O—), 4.58 (dd, 1 H, J=3.67, J=11.98, —CCOOHCH-CHO-CH.sub.2O—), 4.34 (dd, 1H, J=6.61, J=11.98, —CCOOHCH—CHO—CH.sub.2O—), 4.26 (m, 2 H, PO—CH.sub.2—CH.sub.2—NH.sub.2), 4.18 (m, 2 H, —CH.sub.2—OP), 3,62 (m, 2 H, PO—CH.sub.2—CH.sub.2—NH.sub.2), 3.00 (s, 4 H, ONSuc), 2.8 (m, 2 H, CH.sub.2—CO (Ad), 2.50 (m, 4 H, 2×(—CH.sub.2—CO), 2.42 (m, 2 H, —CH.sub.2—CO (Ad), 2.17 (m, 8H, 2×(—CH.sub.2—CH═CH—CH.sub.2—), 1.93 (m, 4 H, COCH.sub.2CH.sub.2CH.sub.2CH.sub.2CO), 1.78 (m, 4 H, 2×(COCH.sub.2CH.sub.2—), 1.43, 1.47 (2 bs, 40 H, 20 CH.sub.2), 1.04. (m, 6 H, 2 CH.sub.3). R.sub.f 0.5 (chloroform-methanol-water, 6:3:0.5.
Preparation of [H-(Gly.sub.2CMGly) .sub.5Gly.sub.2-NHCH.sub.2].sub.3[DE-CO (CH.sub.2) .sub.4CO-(Gly.sub.2CMGly) .sub.5Gly.sub.2-NHCH.sub.2]C, Na, Et.sub.3N-salt (24) (step ii of SCHEME V)
[0077] To a stirred solution of product 20 (522 mg, 0.06821 mmol) in water/2-propanol mixture (16 mL, 2:3) 1M NaHCO.sub.3 (547 μL, 0.547 mmol) and a solution of DE-Ad-OSu (23) 166.1 mg, 0.06821 mmol) in dichloroethane (368 μL) were added, and the solution was stirred for 1.5 h at r.t. After acidification with AcOH (94 μL) the solution was evaporated and the residue was dried in vacuum. Dried mixture was dissolved in 3 mL of water/MeOH (15:1) and put on a C18 reverse phase column (˜45 mL of phase washed with 75% MeOH and then with water/MeOH 15:1). Substances were eluted sequentially with water/MeOH (15:1-50 mL; 9:1-50 mL; 7.5:2.5-50 ml; 1:1-50 mL; 2.5:7.5-100 mL). Unreacted 20 was eluted with water/MeOH 15:1 (Na salt by NMR data, 116 mg, 30.8% of recovery) and with water/MeOH 9:1 (Et.sub.3N salt by NMR data, 63 mg, 13.6% of recovery). Target (H—CMG.sub.5).sub.3C(CMG.sub.5-Ad-DE) (24) was eluted with water/MeOH 1:1. Yield of pure freeze-dried product 24 was 135 mg (25.5% on (24)), white solid. TLC (1:2:1 (v/v/v) MeOH/ethyl acetate/water): 20 R.sub.f 0.06; 24 R.sub.f 0.17.
[0078] (H—CMG.sub.5).sub.3C(CMG.sub.5-Ad-DE) Na.sub.1(Et.sub.3N).sub.20 (24): .sup.1H NMR (700 MHz, [D.sub.2]H.sub.2O/[D.sub.4]CH.sub.3OH 2:1 (v/v), 30° C.) δ, ppm: 5.561 (m, 4 H; 2 cis CH═CH of DE), 5.454 (m, 1 H; OCH.sub.2—CH(OCO)CH.sub.2O of DE), 4.629 (dd, 1 H, J=12.3 Hz/2 Hz; OCH.sub.2—CH(OCO)CHOCO of DE), 4.462-4.057 (181 H; 20 NCH.sub.2CO, 20 NCH.sub.2—COOH, 48 COCH.sub.2NH, OCH.sub.2—CH(OCO)CHOCO of DE, OCH.sub.2CH.sub.2NH of DE), 3.597 (t, 2 H, J=5 Hz; OCH.sub.2CH.sub.2NH of DE), 3.226 (q, 102 H, J-7.3 Hz; 51 NCH.sub.2CH.sub.3), 3.099 (broad.s, 8 H; 4 C—CH.sub.2NH), 2.557, 2.532, 2.522 and 2.456 (triplets, total 8 H; 4 CO—CH.sub.2CH.sub.2), 2.203 (˜dd, 8 H, J-12 Hz/5.8 Hz; 2 CH.sub.2—CH═CH—CH.sub.2, of DE), 1.807 and 1.783 (multiplets, 8 H; 4 CO—CH.sub.2CH.sub.2), 1.526 and. 1.475 (overlapping m and t, total 193 H; m, 20 CH.sub.2 of DE; t, J=7.3 Hz, 51 NCH.sub.2CH.sub.3), 1.063 (t, 6 H, J=7 Hz; 2 CH.sub.3 of DE). MALDI TOF mass-spectrum, M/Z: 6028, M+H; 6050, M+Na.
Preparation of 3-trifluoroacetamidopropyl-3,4-di-O-acetyl-2,6-di-O-benzyl-α-D-galactopyranosyl-(1.fwdarw.3)-2,4-di -O-acetyl 6-O-benzyl-β-D galactopyranosyl-(1.fwdarw.4)-2-acetamido-3-O-acetyl-6-O-benzyl-2-deoxy-β-glucopyranoside (27) (step i of SCHEME VI)
[0079] The glycosyl acceptor (3-trifluoroacetamidopropyl)-2-acetamido-3-O-acetyl-6-O-benzyl-2-deoxy-4-O-(2,4-di-O-acetyl-6-O-benzyl-β-D-galactopyranosyl)-β-D-glucopyranoside (25) was prepared according to the method disclosed in the method disclosed in the publication of Pazynina et al (2008). A mixture of the glycosyl acceptor 25 (500 mg, 0.59 mmol), thiogalactopyranoside 26 (576 mg, 1.18 mmol), NIS (267 mg, 1.18 mmol), anhydrous CH.sub.2Cl.sub.2 (25 ml) and molecular sieves 4 Å (500 mg) was stirred at −45° C. for 30 min under an atmosphere of Ar. A solution of TfOH (21 μl, 0.236 mmol) in anhydrous CH.sub.2Cl.sub.2 (0.5 ml) was then added. The reaction mixture was stirred for 2 h at −45° C. and the temperature was then increased to −20° C. over 4 h. The mixture was kept at −20° C. overnight. Then extra amounts of thiogalactopyranoside 26 (144 mg, 0.295 mmol), NIS (66 mg, 0.295 mmol) and TfOH (5 μl, 0.06 mmol) were added and the stirring maintained at −20° C. for 2 h before being allowed to slowly warm up to r.t. (1 h). A saturated aqueous solution of Na.sub.2S.sub.2O.sub.3 was then added and the mixture filtered. The filtrate was diluted with CHCl.sub.3 (300 ml), washed with H.sub.2O (2×100 ml), dried by filtration through cotton wool, and concentrated. Gel filtration on LH-20 (CHCl.sub.3-MeOH) afforded the product 27 (600 mg, 80%), as a white foam.
[0080] .sup.1H NMR (700 MHz, CDCl.sub.3, characteristic signals), δ, ppm: 1.78-1.82 (m, 4 H, CHCHC, OC(O)CH.sub.3), 1.84-1.90 (m, 1 H, CHCHC), 1.91, 1.94, 1.97, 1.98, 2.06 (5 s, 5×3H, 4 OC(O)CH.sub.3, NH(O)CH.sub.3), 3.23-3.30(m, 1 H, NCHH), 3.59-3.65 (m, 1 H, NCHH), 4.05 (m, 1 H, H-2.sup.I), 4.33 (d, 1 H, J.sub.1,27.55, H-1.sup.I), 4.40 (d, 1H, J 12.04, PhCHH), 4.42 (d, 1 H, J.sub.1,2 8.07, H-1.sup.II), 4.45 (d, 1 H, J 11.92, PhCHH), 4.48 (d, 1H, J 12.00, PhCHH), 4.50 (d, 1 H, J 12.00, PhCHH), 4.52 (d, 1 H, J 12.04, PhCHH), 4.54 (d, 1 H, J 12.00, PhCHH), 4.57 (d, 1 H, J 12.00, PhCHH), 4.64 (d, 1 H, J 11.92, PhCHH), 4.99 (dd≈t, 1 H, J 8.24, H-2.sup.II), 5.08-5.13 (m, 2 H, H-3.sup.I,H-3.sup.III), 5.23 (d, 1 H, J.sub.1,2 3.31, H-1.sup.III), 5.46 (d, 1 H, J.sub.3,4 2.25, H-4.sup.II), 5.54 (d, 1H, J.sub.3,4 3.11, H-4.sup.III), 7.20-7.40 (m, 20 H, ArH); 7.49-7.54 (m, 1 H, NHC(O)CF.sub.3). R.sub.f0.4 (PhCH.sub.3-AcOEt 1:2).
Preparation of 3-aminopropyl-α-D-galactopyranosyl-(1.fwdarw.3)-β-D-galactopyranosyl-(1.fwdarw.4)-2-acetamido-2-deoxy-β-D-glucopyranoside (29) (steps ii and iii of SCHEME VI)
[0081] The product 27 (252 mg, 0.198 mmol) was deacetylated according to Zemplen (8 h, 40° C.), neutralized with AcOH and concentrated. The TLC (CH.sub.3Cl-MeOH, 10:1) analysis of the obtained product showed two spots: the main spot with R.sub.f 0.45, and another one on the start line (ninhydrin positive spot) that was an indication of partial loss of trifluoroacetyl. Therefore, the product was N-trifluoroacetylated by treatment with CF.sub.3COOMe (0.1 ml) and Et.sub.3N (0.01 ml) in MeOH (10 ml) for 1 h, concentrated and subjected to column chromatography on silica gel (CHCl.sub.3-MeOH, 15:1) to afford the product 28 as a white foam (163 mg, 77%, R.sub.f 0.45 (CH.sub.3Cl-MeOH, 10:1). The product 28 was subjected. to hydrogenolysis (200 mg Pd/C, 10 ml MeOH, 2 h), filtered, N-defluoroacetylated (5% Et.sub.3N/H.sub.2O, 3 h) and concentrated. Cation-exchange chromatography on Dowex 50×4-400 (H.sup.+) (elution with 5% aqueous ammonia) gave the product 29 (90 mg, 98%) as a white foam.
##STR00015## ##STR00016## ##STR00017##
##STR00018##
[0082] .sup.1H NMR (D.sub.2O, characteristic signals), δ, ppm: 1.94-1.98 (m, 2 H, CCH.sub.2C), 2.07 (s, 3 H, NHC(O)CH.sub.3), 3.11 (m, J 6.92, 2 H, NCH.sub.2), 4.54 and 4.56 (2d, 2 H, J.sup.1,2 8.06, J.sub.1,2 7.87, H-1.sup.I and H-1.sup.II), 5.16 (d, 1 H, J.sub.1,2 3.87, H-1.sup.III). R.sub.f 0.3 (EtOH-BuOH-Py-H.sub.2O-AcOH; 100:10:10:10:3).
Preparation of 3-aminopropyl 2-acetamido-2-deoxy-α-D-qalactopyranosyl-(1.fwdarw.3)-β-D-galactopyranosyl-(1.fwdarw.4)-2-acetamido-2-deoxy-β-D-glucopyranoside (33) (steps i to iii of SCHEME VII)
[0083] The glycosyl chloride 3,4,6-tri-O-acetyl-2-azido-2-desoxy-β-D-galactopyranosylchloride (30) was prepared according to the method disclosed in the publication of Paulsen et al (1978). A solution of the glycosyl acceptor 25 (420 mg, 0.5 mmol), silver triflate (257 mg, 1.0 mmol.), tetramethylurea (120 μl, 1.0 mmol) and freshly calcinated molecular sieves 4 Å in dry dichloromethane (20 ml), were stirred at room temperature in darkness for 30 min. Another portion of sieves 4 Å was added, and a solution of glycosyl chloride 30 (350 mg, 1.0 mmol) in dry dichloromethane (3 ml) was added. The mixture was stirred for 20 h at room temperature. The resin was filtered and washed with methanol (4×10 ml), then solvent was evaporated. Chromatography on silica gel (elution with 5-7% isopropanol in chloroform) yielded 407 mg (70%) of the product 31 as a mixture of anomers (α/β-3.0 as determined by .sup.1H-NMR spectroscopy).
[0084] A solution of the product 31 (407 mg, 0.352 mmol) in methanol (30 ml) was subjected to hydrogenolysis over 400 mg 10% Pd/C for 16 h. Then the resin was filtered off, washed with methanol (4×10 ml) and the product concentrated in vacuum. The dry residue was acetylated with 2:1 pyridine-acetic anhydride mixture (6 ml) at 20° C. for 16 h, the reagents being co-evaporated with toluene. Two chromatography steps on silica gel (elution with 10% isopropanol in ethyl acetate and with 5-10% methanol in chloroform) resulted in 160 mg (42%) of the product 32 and 39 mg (10%) of the product 32β.
[0085] A solution of 2 M sodium methylate in methanol. (200 μl) was added to a solution of the product 32 (160 mg, 0.149 mmol) in dry methanol (4 ml). The solution was evaporated after 1 h, 4 ml water added and the solution kept for 16 h before being chromatographed on a Dowex-H′ column (elution with 1 M ammonia). The eluate was evaporated, lyophilized to yield 87.2 mg (91%) of the 3-aminopropyltrisaccharide (33).
[0086] .sup.1H NMR spectra were recorded on a Bruker Biospin GmbH spectrometer at 303K. Chemical shifts (δ) for characteristic protons are provided in ppm with the use of HOD (4.750), CHCl.sub.3 (0 7.270) as reference. Coupling constants (J) are provide in Hz. The signals in .sup.1H NMR spectra were assigned using a technique of spin-spin decoupling (double resonance) and 2D-.sup.1H,.sup.1H—COSY experiments.
[0087] The values of optical rotation were measured on a digital polarimeter Perkin Elmer 341 at 25° C.
[0088] Mass spectra were registered on a MALDI-TOF Vision-2000 spectrometer using dihydroxybenzoic acid as a matrix.
[0089] 32: .sup.1H-NMR (700 MHz, CDCl.sub.3): 1.759-1.834 (m, 1 H, CH sp); 1.853-1.927 (m, 1 H, CH sp); 1.972, 1.986, 1.996, 2.046, 2.053, 2.087, 2.106, 2.115, 2.130, 2.224 (10s, 10×3H, COCH.sub.3); 3.222-3.276 (m, 1 H, NCH sp); 3.544-3.583 (m, 1 H, OCH sp); 3.591-3.661 (m 2 H, NCH sp, H-5a), 3.764 (dd≈t, 1 H, H-4a, J 8.8); 3.787 (dd, 1 H, H-3b, 3.7, J.sub.2,3 9.9); 3.836 (br. t, 1 H, H-5b, 7.3); 3.882-3.920 (m, 1 H, OCH sp); 3.950 (dd, 1 H, H-6′c, J.sub.6′,6″10.6, J.sub.5,6′5.2); 4.009 (ddd, 1 H, H-2a, J.sub.1,2 7.9, J.sub.2,3 10.0, J.sub.2,NH 9.0); 4.076-4.188 (m, 5 H, H-6′a, H-6′b, H-6″b, H-5c, H-6″c); 4.415 (d, 1H, H-1a, J.sub.1,2 7.9); 4.443 (d, 1 H, H-1b, J.sub.1,2 7.9); 4.529 (dd, 1 H, H-6″a, J.sub.6′,6″12.0, J.sub.5,6″2.5); 4.548 (ddd, 1 H, H-2c, J.sub.1,2 3.4, J.sub.2,3 11.6, J.sub.2,NH 9.4); 4.893 (dd, 1 H, H-3c, J.sub.3,4 3.1, J.sub.2,3 11.6); 5.021 (d, 1 H, H-1c, J.sub.1,2 3.4); 5.039-5.075 (m 2 H, H-3a, H-2b); 5.339 (dd≈d, 1 H, H-4b, J 2.9); 5.359 (dd, 1 H, H-4c, J.sub.3,4 2.7, J.sub.4,5 0.9); 5.810 (d, 1 H, NHAc a, J.sub.2,NH a,J.sub.2,NH 9.0); 6.184 (d, 1 H, NHAc c, J.sub.2,NH 9.4); 7.310-7.413 (m, 1 H, NHCOCF.sub.3 sp). R.sub.f 0.31 (EtOAc-iPrOH, 10:1). MS, m/z calculated for [C.sub.43H.sub.60N.sub.3F.sub.3O.sub.25]H.sup.+: 1076.35, found 1076.
[0090] 32β: .sup.1H-NMR (700 MHz, CDCl.sub.3): 1.766-1.832 (m, 1 H, CH sp); 1.850-1.908 (m, 1 H, CH sp); 1.923, 1.969, 1.982, 2.059, 2.071, 2.099 (2), 2.120, 2.136, 2.148 (10s, 10×3H, COCH.sub.3); 3.230-3.289 (m, 1 H, NCH sp); 3.521 (ddd, 1 H, H-2c, J.sub.1,2 8.2, J.sub.2,3 11.2, J.sub.2,NH 7.8); 3.548-3.591 (m 1 H, OCH sp); 3.591-3.648 (m, 2 H, NCH sp, H-5a); 3.743 (dd≈t, 1 H, H-4a, J 8.6); 3.795 (br. t, 1 H, H-5b, J 3 6.5); 3.852 (dd, 1 H, H-3b, J.sub.3,4 3.6, J.sub.2,3 9.9); 3.873-3.923 (m, 2 H, H-5c, OCH sp); 4.002 (ddd, 1 H, H-2a, J.sub.1,2 8.0, J.sub.2,3 9.5, J.sub.2,NH 8.9); 4.039 (dd, 1 H, H-6′b, J.sub.6′,6″ 11.6; J.sub.5,6′ 6.9); 4.087-4.144 (m, 3 H, H-6′a, H-6″b, H-6′c); 4.160 (dd, 1 H, H-6″c, J.sub.6′,6″ 11.2, J.sub.5,6″ 6.0); 4.409, 4.417 (2d≈t, 2×1H, H-1a, H-1b, J 7.6); 4.519 (dd, 1 H, H-6″a, J.sub.6′,6″ 11.8, J.sub.5,6″ 2.5); 4.992 (d, 1 H, H-1c, J.sub.1,2 8.2); 5.043 (dd, 1 H, H-3a, J.sub.3,4 8.6, J.sub.2,3 9.5); 5.066 (dd, 1 H, H-2b, J.sub.1,2 8.0, J.sub.2,3 9.8); 5.350 (dd≈d, 1 H, H-4c, J 3.2); 5.372 (dd≈d, 1 H, H-4b, J 3.4); 5.399 (d, 1 H, NHAc c, J.sub.2,NH 7.8); 5.449 (dd, 1 H, H-3c, J.sub.3,4 3.4, J.sub.2,3 11.3); 5.856 (d, 1 H, NHAc a, J.sub.2,NH 8.9); 7.361-7.466 (m, 1 H, NHCOCF.sub.3 sp). R.sub.f 0.24 (EtOAc-iPrOH, 10:1). MS, m/z calculated for [C.sub.43H.sub.60N.sub.3F.sub.3O.sub.25]H.sup.+: 1076.35, found 1076.
##STR00019##
[0091] 33: .sup.1H-NMR (700 MHz, D.sub.2O): 1.924-2.002 (m, 2 H, CH.sub.2 sp); 2.060, 2.064 (2s, 2×3H, NCOCH.sub.3); 3.102 (m≈t, 2 H, NCH.sub.2 sp, J 6.8); 3.592-3.644 (m, 1 H, H-5a); 3.655 (dd, 1 H, H-2b, J.sub.1,2 7.9, J.sub.2,3 9.9); 3.702 (br. dd, 1 H, H-5b, J.sub.5,6′ 3.8, J.sub.5,6″ 8.2, J.sub.4,5 ≦1); 3.713-3.815 (m, 9 H); 3.846 (dd, 1 H, H-6′, J.sub.6′,6″ 12.3, J.sub.5,6′ 5.3); 3.984-4.062 (m, OH, OCH sp, H-6″a, H-4b, H-3c); 4.123 (dd≈d, 1 H, H-4c, J 2.9); 4.206 (br. t, 1 H, H-5c, J 6.3); 4.248 (dd, 1 H, H-2c, J.sub.1,2 3.6, J.sub.2,3 11.0); 4.542 (2d≈t, 2 H, H-1a, H-1b, J 7.4); 5.100 (d, 1 H, H-1c, J.sub.1,2 3.5). R.sub.f 0.55 (MeOH -1M aq. Py.Math.AcOH, 5:1). MS, m/z calculated for [C.sub.25H.sub.45N.sub.3O.sub.16]H.sup.+: 644.28; found 644. [α].sub.546 nm+128 (c 0.3; MeCN-H.sub.2O, 1:1).
[0092] 33β: .sup.1H-NMR (700 MHz, D.sub.2O): 1.938-1.991 (m, 2 H, CH.sub.2 sp); 2.055, 2.062 (2s, 2×3H, NCOCH.sub.3); 3.100 (m≈t, 2 H, NCH.sub.2 sp, J 6.9); 3.610 (dd, 1 H, H-2b, J.sub.1,2 7. 9, J.sub.2,3 9.9); 3.603-3.636 (m, 1 H, H-5a); 3.682 (br. dd, 1 H, H-5b, J.sub.5,6′ 4.9, J.sub.5,6″ 7.8, J.sub.4,5≦1); 3.693-3.826 (m, 11 H); 3.842 (dd, 1 H, H-6′a, J.sub.6′,6″ ″ 12.1, J.sub.5,6′ 5.2); 3.934-3.972 (m, 2 H, H-4b, H-2c); 4.012 (dd, 1 H, H-6″a, J.sub.6′,6″ 12.2, J.sub.5,6″ 2.0); 4.023-4.057 (m, 1 H, OCH sp); 4.175 (dd≈d, 1 H, H-4c, J 2.9); 4.478 (d, 1 H, H-1b, J.sub.1,2 7.9); 4.531 (d, 1 H, H-1a, J.sub.1,2 8.1); 4.638 (d, 1 H, H-1c, J.sub.1,2 8.4), R.sub.f 0.48 (MeOH-1M aq. Py.Math.AcOH, 5:1). MS, m/z calculated for [C.sub.25H.sub.46N.sub.5O.sub.16]H.sup.1: 644.28; found 644. [α].sub.546 nm +6 (c 0.3; MeCN-H.sub.2O, 1:1).
Preparation of Galili-T-17-DE (35) (step ii of SCHEME VIII)
[0093] Compound 24 (4.3 mg, 5 μmol) and Et.sub.3N (0.5 μl) in H.sub.2O (0.75 ml) was added to a stirred solution of compound 34 (5 mg, 6 μmol) in dry DMSO (0.3 mL) in 3 portions during 1.5 h. The mixture was stirred for 24 h at room temperature and then subjected to column chromatography (Sephadex LH-20, MeOH-H.sub.2O, 3:7) to yield the crude product 35. The product was lyophilized from water, the residue was dissolved in 3 ml of water, aqueous solution of NaHCO.sub.3 (10 mM) was added to pH 6.5 and the solution was lyophilized to provide 3.7 mg of the compound 35 as Na-salt.
[0094] .sup.1H NMR (700 MHz, D.sub.2O/CD.sub.3OD, 2:1 (v/v), selected chemical shifts) δ, ppm: 1.06 (t, J 7.03 Hz, CH.sub.3 of DE), 1.28-1.61 (m, CH.sub.2 DE), 1.71-1.88 (m, —COCH.sub.2CH.sub.2CH.sub.2CH.sub.2CO and —COCH.sub.2CH.sub.2—), 1.90-1.99 (m, OCH.sub.2CH.sub.2CH.sub.2N), 2.13-2.27 (m, —CH.sub.2CH═CHCH.sub.2—, NHC (O) CH.sub.3), 2.35-2.58 (m, COCH.sub.2CH.sub.2CH.sub.2CH.sub.2CO— and —COCH.sub.2CH.sub.2—), 2.93-3.24 (broad. s, 8 H; 4 C-CH.sub.2NH), 4.63 (dd, J 2.49, J 12.32, C(O)OCHHCHOCH.sub.2O—), 4.67 and 4.70 (2d, J.sub.1,2 7.81, J.sub.1,2 7.95, H-1.sup.I, H-1.sup.II), 5.30 (d, JH.sub.1,2 3.92, H-1.sup.III), 5.42-5.47 (m, —OCH.sub.2-CHO-CH.sub.2O—), 5.52-5.58 (m, 4 H, 2×—CH═CH—). MALDI TOF mass-spectrum, M/Z: 8188 (M+Na.); 8204 (M+K); 8226 (MNa+K).
##STR00020## ##STR00021## ##STR00022##
Preparation of (Mal-βAla-(Gly.sub.2CMGly),.sub.5Gly.sub.2-NHCH.sub.2).sub.3[DE-CO(CH.sub.2).sub.4CO-(Gly.sub.2CMGly) .sub.5Gly.sub.2-NRCH.sub.2]C (37) (SCHEME IX)
[0095] A solution of N-maleoyl-β-alanine N′-hydroxysuccinimide ester (36) (5.3 mg, 20 μmol) in MeCN (500 μL) is added in a single portion to a solution of 25.3 mg (3.3μmol) of compound 24 in 4 mL of 25% aqueous isopropyl alcohol (IPA). The pH of the reaction mixture is adjusted to 7 to 8 with addition of NMM (1:10 (v/v) in IPA, circa 20 μl). The clear solution is kept overnight at room temperature, and the reaction endpoint checked by qualitative spot ninhydrin test. (A negative result in the test indicates the amino component has been consumed). The solvents are removed in vacuum using a rotary evaporator, the oily residue triturated with MeCN (500 μL) and the mixture sonicated for 10 minutes. The slurry obtained is transferred into an Eppendorf tube and centrifuged. The solid is washed repeatedly with absolute ether and MeCN (3×400μL) with sonication followed by centrifugation until no starting reagent (Mal-βAla-ONSu) is detected by TLC (CHCl.sup.3-MeOH-AcOH, 90:8:2 v/v). The precipitate after final ether wash is dried to constant weight in vacuum over 4Å molecular sieves. A quantity of 18.9 mg (70%) of (Mal-βAla-CMG3-NHCH.sub.2).sub.3CCH.sub.2NH-CMG3-Ad-DOPE (37) was obtained as an amorphous white powder. The isolated substance may contain circa 17 moles of tertiary amines and a mole of sodium ion (Na.sup.+) per mole of 37.
[0096] R.sub.f 0.4-0.5, (CHCl.sub.3-MeOH-H.sub.2O, 1:3:1 (v/v/v) plus 0.5% pyridine).
[0097] .sup.1H NMR (700 MHz, [D.sub.2]H.sub.2O/[D.sub.4]CH.sub.3OH 1:1 (v/v), 30° C.) of Na/Et.sub.3N salt (˜7.3 M/M Et.sub.3N) δ, ppm: 7.038 (s, 6H; 3 CH═CH), 5.542 (m, 4 H; 2 cis CH═CH of DE), 5.446 (m, 1 H; OCH.sub.2-CH(OCO)CH.sub.2O of DE), 4.635 (dd, 1 H, J=12.2 Hz/2.3 Hz; OCH.sub.2—CH(OCO)CHOCO of DE), 4.516-4.041 (181 H; 20 NCH.sub.2CO, 20 NCH.sub.2COOH, 48 COH.sub.2NH, OCH.sub.2—CH(OCO)CHOCO of DE, OCH.sub.2CH.sub.2NH of DE), 3.985 (t, J=6.8 Hz, 6 H; 3 NCH.sub.2 of Ala), 3.594 (t, 2 H, J=4.5 Hz; OCH.sub.2CH.sub.2NH of DE), 3.384 (q, 44 H, J=7.3 Hz; 22 NCH.sub.2CH.sub.3), 3.079 (broad.s, 8 H; 4 C-CH.sub.2NH), 2.777 (t, 6 H, J=6.8 Hz; 3 CH.sup.2CO of Ala), 2.548, 2.522, 2.515 and 2.449 (triplets, total 8 H; 4 CO-CH.sub.2CH.sub.2), 2.195 (˜dd, 8 H, J=11.5 Hz/5.8 Hz; 2 CH.sub.2—CH═CH—CH.sub.2 of DE), 1.812 and 1.776 (multiplets, 8 H; 4 CO-CH.sub.2CH.sub.2), 1.484 and 1.454 (overlapping t and m, total 106 H; t, J=7.3 Hz, 22 NCH.sub.2CH.sub.3; m, 20 CH.sub.2 of DE), 1.061 (t, 6 H, J=7.1 Hz; 2 CH.sub.3 of DE).
##STR00023## ##STR00024##
##STR00025## ##STR00026##
Preparation o f (MU T21-Mal -βAla-(Gly.sub.2CMGly) .sub.5Gly.sub.2-NHCH.sub.2) .sub.3[DE-CO (CH.sub.2) .sub.4CO-(Gly.sub.2CMGly) .sub.5Gly.sub.2-NHCH.sub.2]C (38) (SCHEME X)
[0098] A quantity (12.5 rag, 7.4 μmol) of the 14-mer oligopeptide designated MUT21 (m.w. 1693.17Da):
SerGlnThrAsnAspLysHisLysArgAspThrTyrProCys (SEQ ID NO: 01)
is prepared as a solution in 4 mL 0.1 M NMM in 30% aqueous isopropyl alcohol, pH 6.6. The solution is combined with of the same buffer, in which a quantity (13.5 mg, 1.64 μmol) of 37 has been dissolved. The reaction mixture is stirred overnight at room temperature and centrifuged. The supernatant is dialyzed against unbuffered 30% (v/v) IPA-water for 24 hours and Milli-Q water using a dialysis bag with a cutoff molecular weight of 3.5 kDa (Spectra/Por 3) to remove residual oligopeptide material. The slurry obtained is then transferred into a lyophilization flask and freeze-dried to a constant weight. A quantity of 18.4 mg (84%) of construct 38 is obtained as an amorphous white powder. The expected signals ratio of low-field protons characteristic of peptide and lipid parts of the construct is revealed in .sup.1H NMR (3 mg/mL in D.sub.2O/CD.sub.3OD 2:1, 303 K, 700 MHz) (
[0099] Comparative Chemistry
Preparation of {[2-(2-tert-butoxycarbonylamino-acetylamino)-acetyl]-methoxycarbonylmethyl-amino}-acetic acid methyl ester (7) (step i of COMPARATIVE SCHEME I)
[0100] An alternative method of preparing compound 7 was employed. N-Methylmorpholine (11.0 ml, 0.1 mol) was added to a stirred suspension of Boc-glycyl-glycine (23.2 g, 0.1 mol) in 150 ml methylene chloride, the solution was cooled to −15° C. and isobutyl chloroformate (13.64 g, 0.1 mol) was added for 10 min. Then 1-hydroxybenzotriazole and the solution of (methoxycarbonylmethylamino)-acetic acid methyl ester (7) (16.1 g, 0.1 mol) in 50 ml DMF were added to the compound 39 containing reaction mixture at the same temperature. The resulting mixture was stirred for 30 min at 0° C. then for 2 h at ambient temperature and evaporated to dryness. The residue was dissolved in 200 ml of methylene chloride and washed with 100 ml 0.5 M HCl and 200 ml 2% aq. NaHCO.sub.3. Solvents were evaporated in vacuum and the residue was purified with column chromatography on silica gel (3% MeOH in CHCl.sub.3) to give pure compound 7 (34.08 g, 91%) as a colourless glass. TLC: R.sub.t=0.40 (5% MeOH in CHCl.sub.3), R.sub.f=0.49 (7:1 (v/v) chloroform/methanol).
[0101] .sup.1H NMR (500 MHz, [D.sub.6]DMSO, 30° C.) δ, ppm: 7.826 (t, J-5.1 Hz, 1 H; NHCO), 6.979 (t, J=5.9 Hz, 1 H; NHCOO), 4.348 and 4.095 (s, 2 H; NCH.sub.2COO), 3.969 (d, J=5.1 Hz, 2H; COCH.sub.2NH), 3.689 and 3.621 (s, 3 H; OCH.sub.3), 3.559 (d, J=5.9 Hz, 2 H; COCH.sub.2NHCOO), 1.380 (s, 9 H; C(CH.sub.3).sub.3). R.sub.f 0.49 (7:1 (v/v) chloroform/methanol).
Preparation of {[2-(2-tert-butoxycarbonylamino-acetylamino)-acetyl]-methoxycarbonylmethyl-amino}-acetic acid (8) (step ii of COMPARATIVE SCHEME I)
[0102] 0.2 M aqueous NaOH (325 ml) was added to a stirred solution of {[2-(2-tert-butoxycarbonylamino-acetylamino)-acetyl]-methoxycarbonylmethyl-aminol}-acetic acid methyl ester (8) (24.42 g, 65.12 mmol) in methanol (325 ml), reaction mixture was kept for 15 min at ambient temperature, acidified with acetic acid (5 ml) and evaporated to dryness. Column chromatography of the residue on silica gel (methanol-ethyl acetate 1:1) gave the target compound as Na-salt (20.44 g) which was dissolved in methanol/water/pyridine mixture (20:10:1, 350 ml) and passed through ion-exchange column (Dowex 50×4-400, pyridine form, 300 ml) to remove Na cations. Column was washed with the same mixture, eluate evaporated and dried in vacuum to give pure compound. 8 (20.15 g, 86%) as a white solid. TLC: Rf=0.47 (iPrOH/ethyl acetate/water 4:3:1).
[0103] .sup.1H NMR (500 MHz, [D.sub.6]DMSO, 30 ° C.), mixture of cis- and trans-conformers of N-carboxymethylglycine unit c.3:1. Major conformer; δ, ppm: 7.717 (t, J=5 Hz, 1 H; NHCO), 7.024 (t, J=5.9 Hz, 1 H; NHCOO), 4.051 (s, 2 H; NCH.sub.2COOCH.sub.3), 3.928 (d, J=5 Hz, 2 H; COCH.sub.2NH), 3.786 (s, 2 H; NCH.sub.2COOH), 3.616 (s, 3 H; OCH.sub.3), 3.563 (d, J=5.9 Hz, 2 H; COCH.sub.2NHCOO), 1.381 (s, 9 H; C(CH.sub.3).sub.3) ppm; minor conformer, δ=7.766 (t, J=5 Hz, 1 H; NHCO), 7.015 (t, J=5.9 Hz, 1 H; NHCOO), 4.288 (s, 2 H; NCH.sub.2COOCH.sub.3), 3.928 (d, J=5 Hz, 2 H; COCH.sub.2NH), 3.858 (s, 2 H; NCH.sub.2COOH), 3.676 (s, 3 H; OCH.sub.3), 3.563 (d, J=5.9 Hz, 2 H; COCH.sub.2NHCOO), 1.381 (s, 9 H; C(CH.sub.3).sub.3). R.sub.f 0.47 (4:3:1 (v/v/v) i-PrOH/ethyl acetate/water).
Preparation of {[2-(2-tort -butoxycarbonylamino-acetylamino)-acetyl]-methoxycarbonylmethyl-amino}-acetic acid N-oxysuccinimide ester (Boc-Gly.sub.2(MCM)GlyOSu) (9) (step iii of COMPARATIVE SCHEME I)
[0104] N,N′-Dicyclohexylcarbodiimide (14.03 g, 68.10 mmol) was added to an ice-cooled stirred solution of {[2-(2-tort-butoxycarbonylamino-acetylamino)-acetyl]-methoxycarbonylmethyl-amino}-acetic acid (26.40 g, 73.13 mmol) and N-hydroxysuccinimide (8.70 g, 75.65 mmol) in DMF (210 ml). The mixture was stirred for 30 min at 0 ° C. then for 2 h at ambient temperature. Precipitated N,N′-dicyclohexylurea was filtered off, washed with DMF (80 ml). The filtrate and washings were concentrated and the residue was stirred with Et.sub.2O (500 ml) for 1 h. Ether extract was decanted and the residue was concentrated to give
##STR00027##
compound 9 as a white foam (32.57 g, 97%). TLC: R.sub.f =0.71 (acetone/acetic acid 40:1). .sup.1H NMR (500 MHz, DMSO[D.sub.6], 30° C.), mixture of cis- and trans-conformers of N-carboxymethylglycine unit c. 3:2.
[0105] Major conformer; δ, ppm: 7.896 (t, J=5.1 Hz, 1 H; NHCO), 6.972 (t, J=5.9 Hz, 1 H; NHCOO) 4.533 (s, 2 H; NCH.sub.2COON), 4.399 (s, 2 H; NCH.sub.2COOCH.sub.3), 3.997 (d, J=5.1 Hz, 2 H; COCH.sub.2NH), 3.695 (s, 3 H; OCH.sub.3), 3.566 (d, J=5.9 Hz, 2 H; COCH.sub.2NHCOO), 1.380 (s, 9 H; C(CH.sub.3).sub.3).
[0106] Minor conformer; δ, ppm: 7.882 (t, J=5.1 Hz, 1 H; NHCO), 6.963 (t, J=5.9 Hz, 1H; NHCOO), 4.924 (s, 2 H; NCH.sub.2COON), 4.133 (s, 2 H; NCH.sub.2COOCH.sub.3), 4.034 (d, J=5.1 Hz, 2 H; COCH.sub.2NH), 3.632 (s, 3 H; OCH.sub.3), 3.572 (d, J=5.9 Hz, 2 H; COCH.sub.2NHOO), 1.380 (s, 9 H; C(CH.sub.3).sub.3).
[0107] R.sub.f 0.71 (40:1 (v/v) acetone/acetic acid).
Preparation of H.sub.2N-CMG2-NH.sub.2 (45) (COMPARATIVE SCHEMES II and III)
[0108] A solution of ethylenediamine (40) (808 mg, 13.47 mmol) and Et.sub.3N (1.87 ml, 13.5 mmol) in DMSO (5 ml) was added to a stirred solution of Boc-Gly.sub.2-(MCM)Gly-OSu (9) (15.42 g, 33.68 mmol) in DMSO (50 ml). The reaction mixture was stirred for 30 min at ambient temperature and acidified with acetic acid (1.2 ml), then fractionated with Sephadex LH-20 column (column volume 1200 ml, eluent-MeOH/water 2:1+0.2% AcOH). Fractions containing compound Boc.sub.2MCMG (41) were combined, solvents evaporated and the residue was concentrated in vacuum. The product was additionally purified by silica gel column chromatography using 2-propanol/ethyl acetate/water (2:6:1) as eluent. Fractions containing pure Boc.sub.2MCMG (41) were combined, solvents evaporated and a residue was dried in vacuum to give target Boc.sub.2MCMG (41) as colourless foam (8.41 g, 84%). TLC: R.sub.f=0.48 (.sup.iPrOH/ethyl acetate/water 2:3:1).
[0109] .sup.1H NMR (500 MHz, [D.sub.6]DMSO, 30° C.), mixture of conformers ˜3:2: 8.166, 8.125, 7.917 and 7.895 (m, total 2 H; 2 CONHCH.sub.2), 7.793 (m, 2 H; NHCH.sub.2CH.sub.2NH), 7.001 (br. t, 2 H; 2 NHCOO), 4.277-3.893 (total 12 H; 2 CH.sub.2COO, 4 NCH.sub.2CO), 3.690 and 3.635 (s, total 6 H; 2 COOCH.sub.3), 3.567 (d, J=5.8 Hz, 4 H; CH.sub.2NHCOO), 3.131 (m, 4 H; NHCH.sub.2CH.sub.2NH), 1.379 (s, 18 H; 2 C(CH.sub.3).sub.3) ppm.
[0110] MS, m/z: 769 [M+Na], 785 [M+K].
[0111] Trifluoroacetic acid (25 ml) was added to a stirred solution of Boc.sub.2MCMG (41) (4.88 g, 6.535 mmol) in methylene chloride (25 ml) and the solution was kept for 1 h at ambient temperature. Then a reaction mixture was concentrated and the residue was evaporated three times with anhydrous MeOH (50 ml), then a residue was extracted three times with Et.sub.2O (100 ml) to remove traces of trifluoroacetic acid. The resulted precipitate (as a white solid) was dried to give 5.06 g (˜100%) of MCMG (42) as bis-trifluoroacetic salt. TLC: R.sub.f=0.23 (ethanol/water/pyridine/acetic acid 5:1:1:1).
[0112] .sup.1H NMR (500 MHz, 30° C.), mixture of conformers ˜5:4: 4.400-4.098 (total 12 H; 2 CH.sub.2COO, 4 NCH.sub.2CO), 3.917 (s, 4 H; 2 COCH.sub.2NH.sub.2), 3.829 and 3.781 (s, total 6 H; 2 COOCH.sub.3), 3.394 (m, 4 H; NHCH.sub.2CH.sub.2NH) ppm.
[0113] MS, m/z: 547 [M+H], 569 [M+Na], 585 [M+K].
[0114] A solution of Boc-Gly.sub.2-(MCM)Gly-OSu (9) (7.79 g, 16.994 mmol) in DMSO (17 ml) and Et.sub.3N (2.83 ml, 20.4 mmol) was added to the stirred solution of H.sub.2N-MCMG-NH.sub.2 (42) (5.06 g, 6.796 mmol) in DMSO (13 ml). The reaction mixture after stirring for 2 h at ambient temperature was acidified with acetic acid (4.0 ml) and fractionated with Sephadex LH-20 column chromatography (column volume 1200 ml, eluent-MeOH/water 2:1+0.2% AcOH). Fractions containing pure Boc.sub.2MCMG2 (43) were combined, solvents evaporated and the residue was dried in vacuum to give target Boc.sub.2MCMG2 (43) as colourless foam (8.14 g, 97%). TLC: R.sub.f=0.25 (.sup.1PrOH/ethyl acetate/water 2:3:1).
[0115] .sup.1H NMR (500 MHz, [D.sub.6]DMSO, 30° C.), mixture of conformers: 8.393-7.887 (total 6 H; 6 CONHCH.sub.2), 7.775 (m, 2 H; NHCH.sub.2CH.sub.2NH), 6.996 (br. t, 2 H; 2 NHCOO), 4.299-3.730 (total 28 H; 4 CH.sub.2CO), 10 NCH.sub.2CO), 3.691 and 3.633 (s, total 12 H; 4 COOCH.sub.3), 3.564 (d, J=5.8 Hz, 4 H; 2 CH.sub.2NHCOO), 3.129 (m, 4 H; NHCH.sub.2CH.sub.2NH), 1.380 (s, 18 H; 2 C(CH.sub.3).sub.3) ppm.
[0116] MS, m/z: 1256 [M+Na], 1271[M+K].
[0117] Boc.sub.2MCMG2 (43) (606 mg, 0.491 mmol) was dissolved in CF.sub.3COOH (2 ml) and the solution was kept for 30 min at r.t. Trifluoroacetic acid was evaporated in vacuum and the residue was extracted three times with E,t.sub.2O (trituration with 25 ml of Et.sub.2O followed by filtration) to remove residual CF.sub.3COOH and the obtained white powder was dried in vacuum. The powder was dissolved in 4 mL of water and then was freeze dried. Yield of H.sub.2N-MCMG2-NH.sub.2 (44) (TFA salt) was estimated as quantitative (actual weight was larger than theoretical by ˜10% due to stability of hydrates). TLC: R.sub.f =0.21 (ethanol/water/pyridine/acetic acid 5:1:1:1).
[0118] .sup.1H NMR (500 MHz, [D.sub.2]H.sub.2O, 30° C.), mixture of conformers: 4.430-4.014 (total 28 H; 4 CH.sub.2COO, 10 NCH.sub.2CO), 3.911 (s, 4 H; 2 COCH.sub.2NH.sub.2), 3.823 and 3.772 (s, total 12 H; 4 COOCH.sub.3), 3.386 (m, 4 H; NHCH.sub.2CH.sub.2NH) ppm.
[0119] MS, m/z: 1034 [M+H], 1056 [M+Na].
[0120] To the solution of H.sub.2N—MCMG2-NH.sub.2 (44) (˜0.49 mmol) in water (20 mL) Et.sub.3N (0.5 mL) was added, and the solution was kept for 15 h at r. t. The reaction mixture was evaporated to dryness and the residue was desalted on Sephadex LH-20 column (two methods): Method A. The residue was dissolved in water (3 ml) and the solution was desalted on Sephadex LH-20 column (column volume 250 mL, eluent MeOH/water 1:1+0.05 M pyridine acetate). Fractions, containing H.sub.2N-CMG2-NH.sub.2 (45) contaminated with salts were combined separately, evaporated and the residue was desalted again. Combined fractions, containing pure H.sub.2N-CMG2-NH.sub.2 (45), were evaporated to ˜4 ml volume and freeze dried. Yield of H.sub.2N-CMG2-NH.sub.2 (45) (internal salt) was 431 mg (90%). Method B. The residue was dissolved in water (3 ml) and the solution was desalted on Sephadex LH-20 column (column volume 250 mL, eluent-MeOH/water 1:1+1%5 conc. aq. NH-.sub.3). Fractions, containing pure H.sub.2N-CMG2-NH.sub.2 (45), were evaporated to ˜4 ml volume and freeze dried. The residue (ammonia salt of H.sub.2N—CMG2-NH.sub.2 (45)) was dissolved in .sup.iPrOH/water 1:1 mixture (10 mL), Et.sub.3N (0.2 mL) was added, and the solution was evaporated to dryness. This procedure was repeated twice; the residue was dissolved in 4 mL of water and freeze-dried. Yield of the di-Et.sub.3N salt of H.sub.2N—CMG2-NH.sub.2 (45) was 549 mg (95%).
[0121] TLC: R.sub.f =0.50 (.sup.iPrOH/MeOH/acetonitrile/water. 4:3:3:4+3% conc. aq. NH.sub.3), or R.sub.f=0.43 (.sup.iPrOH/EtOH/MeOH/water 1:1:1:1, 0.75 M NH.sub.3).
[0122] .sup.1H NMR of H.sub.2N-CMG2-NH.sub.2 (45) internal salt (500 MHz, [D.sub.2]H.sub.2O, 30° C.), mixture of conformers: 4.328-4.006 (total 28 H; 4 CH.sub.2COO, 10 NCH.sub.2CO), 3.907 (s, 4 H; 2 COCH.sub.2NH.sub.2), 3.381 (m, 1 H; NHCH.sub.2CH.sub.2NH) ppm.
[0123] MS, m/z: 977 [M+H], 999 [M+Na], 1015 [M+K].
Preparation of H.SUB.2.N—CMG2-Ad-DOPE (46) (COMPARATIVE SCHEME IV)
[0124] To the intensively stirred solution of H.sub.2N-CMG2-NH.sub.2 (45) (425 mg, 0.435 mmol of internal salt) in i-PrOH/water mixture (i-PrOH/water 3:2, 10 ml) the 1 M aq. solution of NaHCO.sub.3 (0.435 mL, 0.435 mmol) and then the solution of DOPE-Ad-OSu (23) (211 mg, 0.218 mmol) in dichloroethane (0.4 were added. The reaction mixture was stirred for 2 h and then acidified with 0.2 mL of AcOH and evaporated to minimal volume at 35° C. The solid residue was dried in vacuum (solid foam) and then thoroughly extracted with CHCl.sub.3/MeOH mixture (CHCl.sub.3/MeOH 4:1, several times with 10 mL, TLC control). The extracted residue consisted of unreacted H.sub.2N—CMG2-NH.sub.2 (45) and salts (about 50% of H.sub.2N-CMG2-NH.sub.2 (45) was recovered by desalting of combined the residue and a fractions after chromatography on silica gel according to procedure described in the H.sub.2N-CMG2-NH.sub.2 (45) synthesis). The combined CHCl.sub.3/MeOH extracts (solution of H.sub.2N-CMG2-Ad-DOPE (46), DOPE-Ad-CMG2-Ad-DOPE, N-oxysuccinimide and some H.sub.2N-CMG2-NH.sub.2 (45)) were evaporated in vacuum and dried. The obtained mixture was separated on silica gel column (2.8×33 cm, ˜200 mL of silica gel in CHCl.sub.3/MeOH 5:1). The mixture was placed on column in MeOH/CHCl.sub.3/water mixture (MeOH/CHCl.sub.3/water 6:3:1+0.5% of pyridine) and the components were eluted in a stepwise ternary gradient: MeOH/CHCl.sub.3/water composition from 6:3:1 to 6:2:1 and then to 6:2:2 (all with 0.50% of pyridine). DOPE-Ad-CMG2-Ad-DOPE was eluted first (R.sub.f =0.75, MeOH/CHCl.sub.3/water 3:1:1), followed by desired H.sub.2N-CMG2-Ad-DOPE (46) (R.sub.f =0.63, MeOH/CHCl.sub.3/water 3:1:1), last eluted was H.sub.2N—CMG2-NH.sub.2 (45) (R.sub.f =0.31, MeOH/CHCl.sub.3/water 3:1:1). Fractions, containing pure H.sub.2N-CMG2-Ad-DOPE (46) were combined and evaporated to dryness. To remove any low molecular weight
##STR00028##
##STR00029##
impurities and solubilsed silica gel the residue was dissolved in .sup.iPrOH/water 1:2 mixture (2 mL), and was passed through Sephadex LH-20 column (column volume 130 mL, eluent-.sup.1PrOH/water 1:2+0.25% of pyridine). Fractions containing pure H.sub.2N—CMG2-Ad-DOPE (46) were combined and evaporated. (˜20% of 2-propanol was added to prevent foaming) to dryness, the residue was dissolved in water (˜4 mL) and freeze-dried. Yield of H.sub.2N—CMG2-Ad-DOPE (46) was 270 mg (68% on DOPE-Ad-OSu or 34% on H.sub.2N-CMG2-NH.sub.2(45)).
[0125] .sup.1H NMR (500 MHz, [D.sub.2]H.sub.2O[D.sub.4]CH3OH 2:1, 30° C.): 5.505 (m, 4 H; 2 CH.sub.2CH═CHCH.sub.2), 5.476 (m, 1 H; OCH.sub.2CHCH.sub.2O), 4.626 (dd, J.sub.gem=11.6 Hz, 1 H; OCHCHCH.sub.2O), 4.461-4.084 (total 37 H; 4 CH.sub.2COO, 11 NCH.sub.2CO, OCHCHCH.sub.2O, OCH.sub.2CH2N), 4.002 (s, 2 H; COCH.sub.2NH.sub.2), 3.573 (m, 4 H; NHCH.sub.2CH.sub.2NH), 2.536-2.463 (m, total 8 H; 4 CH.sub.2CO), 2.197 (m, 8 H; 2 CH.sub.2CH═CHCH.sub.2), 1.807 (m, 8 H; 4 CH.sub.2CH.sub.2CO), 1.480 (m, 40 H; 20 CH.sub.2), 1.063 (˜t, J≈6 Hz, 6 H; 2 CH.sub.3) ppm.
[0126] MS, m/z: 1831 [M+H].
Preparation of Galili-CMG2-Ad-DOPE (47) (COMPARATIVE SCHEME V)
[0127] To a stirred solution of compound 34 (66 mg, 0.079 mmol) in dry DMSO (6 mL) were added 15 μl Et.sub.3N and powdered H.sub.2N-CMG2-Ad-DOPE (46) (95 mg, 0.0495 mmol) in 3 portions. The mixture was stirred for 24 h at room temperature and then subjected to column chromatography (Sephadex LH-20, i-PrOH-H.sub.2O, 1:2, 0.5 v % Py, 0.25 v % AcOH) to yield the crude compound 47 in a form of Py-salt; The compound was lyophilized from water two times, then dissolved again in 10 ml of water, aqueous solution of NaHCO.sub.3 (50 mM) was added to pH 6.5 for obtaining the compound 47 in a form of Na-salt and the solution was subjected to lyophilization. The yield of compound 47 (Na-salt) was 114 mg (86% based on NH.sub.2—CMG.sub.2—DE), R.sub.f 0.6 (i-PrOH-MeOH-MeCN-H.sub.2O, 4:3:6:4), .sup.1H NMR (700 MHz, D.sub.2O—CD.sub.3OD, 1:1 (v/v), 40° C.; selected signals) δ, ppm: 1.05 (t, J 7.03 Hz, 6 H; 2 CH.sub.3), 1.40-1.58 (m, 40 H; 20 CH.sub.2), 1.73-1.87 (m, 12 H; 2×-COCH.sub.2CH.sub.2CH.sub.2CH.sub.2CO and 2×—COCH.sub.2CH.sub.2-), 1.90-1.99 (m, 2 H; OCH.sub.2CH.sub.2CH.sub.2N), 2.15-2.25 (m, 11 H; 2×—CH.sub.2CH═CHCH.sub.2-, NHC (O) CH.sub.3), 2.39-2.59 (2 m, total 12 H, 2×—COCH.sub.2CH.sub.2CH.sub.2CH.sub.2CO— and 2×—COCH.sub.2CH.sub.2-) 4.63 (dd, 1 H, J 2.51, J 12.20, C(O)OCHHCHOCH.sub.2O—), 4.67 and 4.69 (2d×1H, J.sub.1,2 7.81, J.sub.1,2 7.95, H-1.sup.T, H-1.sup.TT), 5.30 (d, 1 H, J.sub.1,2 3.88, H-1.sup.TTT), 5.42-5.46 (m, 1 H, —OCH.sub.2—CHO—CH.sub.2O—), 5.49-5.59 (m, 4 H, 2×—CH═CH—); MALDI TOF mass-spectrum, M/Z: 2567 (M+Na); 2583 (M+K); 2589 (MNa+Na); 2605 (MNa+K); 2611 (MNa.sub.2+Na).
##STR00030##
##STR00031## ##STR00032##
Preparation of GalNAcα1-3Galβ1-4GlcNAc-Ad-DOPE (33) (COMPARATIVE SCHEME VI)
[0128] To a solution of the product 23 (33 μmol) in N,N-dimethylformamide (1 ml), 30 μmol of the 3-aminopropyltrisaccharide 33 and 5 μl of triethylamine (Et..sub.3N) were added. The mixture was stirred for 2 h at room temperature. Column chromatography on silica gel (CH.sub.2Cl.sub.2-EtOH-H.sub.2O; 6:5:1) provided an 81% yield of the construct 48.
[0129] 48: .sup.1H NMR (700 MHz, CDCl.sub.3-CD.sub.3OD, 1:1 v/v, selected), δ, ppm: 1.05 (t, 6H, J 7.05, 2 CH.sub.3), 1.39-1.55 (m, 40 H, 20 CH.sub.2), 1.75-1.84 (m, 8 H, COCH.sub.2CH.sub.2CH.sub.2CH.sub.2O and 2× COCH.sub.2CH.sub.2-), 1.84-1.96 (m, 2 H, O—CH.sub.2CH.sub.2CH.sub.2-NH), 2.15-2.22 (m, 14 H, 2×(—CH.sub.2—CH═CH—CH.sub.2—), 2× NHC (O) CH.sub.3), 2.34-2.46 (m, 4 H, 2×-CH.sub.2—CO), 2.36-2.44 (m, 4 H, 2×-CH.sub.2-CO), 3.29-3.34 (m, 1 H, —CH.sub.2—CHH—NH), 4.17-1.20 (m, 2 H, —CHO—CH.sub.2OP—), 4.34-4.39 (m, 2 H, —CH.sub.2OPO—CH.sub.2—CH.sub.2), 4.57 (d, 1 H, J.sub.1,2 8.39, H-1.sup.I), 4.50 (dd, 1 H, J 3.78, J 10.82, —C(O)OCHHCHOCH.sub.2O—), 4.58-4.61 (m, 2 H, H-1.sup.II, C(O)OCHHHCHOCH.sub.2O—), 5.15 (d, 1 H, J.sub.1,2 3.76, H-1.sup.III), 5.38-5.42 (m, 1 H, —OCH.sub.2-CHO—CH.sub.2O—), 5.47—) 5.53 (m, 4H, 2×—CH—CH—). R.sub.f 0.5 (CH.sub.2Cl.sub.2-EtOH-H.sup.2O; 6:5:1).
##STR00033##
Preparation of Galα1-3Galβ1-4GlcNAc-Ad-DOPE (49) (COMPARATIVE SCHEME VII)
[0130] Construct 49 was prepared according to the same method employed for the preparation of construct 48. Eluent for column chromatography on silica gel: CH.sub.2Cl.sub.2-EtOH-H.sub.2O; 6:5:1, yield of construct 49-84%;
[0131] 49: .sup.1H NMR (700 MHz, CDCl.sub.3-CD.sub.3OD, 1:1 v/v, selected signals), δ, ppm: 1.05 (t, 6 H, J 6.98, 2 CH.sub.3), 1.36-1.55 (m, 40 H, 20 CH.sub.2), 1.73-1.84 (m, 8 H, COCH.sub.2CH.sub.2CH.sub.2CH.sub.2CO and 2×(COCH.sub.2CH.sub.2-), 1.85-1.96 (m, 2 H, O—CH.sub.2CH.sub.2CH.sub.2—NH), 2.14-2.22 (m, 11 H, 2×(—CH.sub.2—CH═CH—CH.sub.2—), NHC(O)CH.sub.3), 2.45-2.52 (m, 4 H, 2×—CH.sub.2—CO), 2.36- 2.45 (m, 4 H, 2×—CH.sub.2—CO), 3.29-3.35 (m, 1 H, —CH.sub.2-CHH—NH), 3.52-3.62 (m, 3 H, PO—CH.sub.2-CH.sub.2—NH, —CH.sub.2—CHHH—NH), 4.13-4.18 (m, 2 H, —CHO—CH.sub.2OP—), 4.19 (d, 1 H, J.sub.3,4 2.48, H-4.sup.II) 4.36 (dd, 1 H, J 6.8, J 12.00, —C(O)OCHHCHOCH.sub.2O—), 4.56 (d, 1 H, J.sub.1,2 8.39, H-1.sup.I), 4.60 (dd, 1 H, J 2.87, J 12.00, C(O)OCHHCHOCH.sub.2O—), 4.61 (d, 1 H, J.sub.1,2 7.57, H-1.sup.II), 5.18 (d, 1 H, J.sub.1,2 2.52, H-1.sup.III), 5.34-5.43 (m, 1 H, —OCH.sub.2—CHO—CH.sub.2O—), 5.45-5.54 (m, 4 H, 2×—CH═CH—). R.sub.f0.45 (CH2.sub.Cl.sub.2-EtOH—H.sub.2O; 6:5:1),
##STR00034##
[0132] Biology
Preparation of kodecytes
[0133] Stock solutions of constructs (35, 47, 48 and 49) were prepared at a concentration of 1 mg/mL in a red blood cell (RBC) preservative solution (CELPRESOL™, CSL Limited). Prior to dilution each stock solution was vortexed for 45 seconds at room temperature (r.t.). A volume of 100 μL of diluted stock solution was added to a volume of 100 μL centrifugally packed RBCs (packed cell volume; PCV). The total volume of 200 μL suspended RBCs was incubated at 37° C. for 2 hours before washing with CELPRESOL™ and re-suspending the modified RBCs (“kodecytes”) at a concentration of 5% PCV in CELPRESOL™.
Preparation of Drabkins solution
[0134] Amounts of 200 mg potassium ferricyanide (K.sub.3Fe(CN).sub.6), 50 mg potassium cyanide (KCN) and. 140 mg potassium dihydrogen phosphate (KH.sub.2PO.sub.4) and a volume of 1 μmL nonionic surfactant (Triton X-100) were dissolved in deionised water and made up to a volume of 1 L. The solution was stored in glass bottles in the dark and pH confirmed to be in the range 7.0 to 7.4 before use.
Preparation of EDTA solution
[0135] Amounts of 4.45 g ethylenediaminetetraacetic acid (EDTA) as its dipotassium salt (K.sub.2H.sub.2EDTA) and 0.3 g sodium hydroxide (NaOH) were dissolved in deionised water and made up to a volume of 100 mL.
Detection of antibodies in patient plasma
[0136] The ability of kodecytes prepared using different constructs to detect the presence of antibodies in samples of plasma was compared by a method analogous to that described in Bovin et al (2009). The results are presented in Table 1 and are consistent with an increased avidity for MUT21 binding antibodies (if present) in the sera of subjects.
Complement induced cell lysis
[0137] Prior to use kodecytes were washed and re-suspended 5% PCV in phosphate buffered saline (PBS). Uniformity of concentration of RBCs was confirmed by adding a volume of 40 μL of kodecyte suspension to a volume of 1 mL of Drabkins solution and the absorbance measured at 540 nm against Drabkins solution (blank). Variations in measured absorbances was reduced to less than 10% by adjustment of suspending volume.
[0138] The ability of constructs to induce complement mediated autolysis was evaluated by a method analogous to that described in the publication of Henry and Komarraju (2012). For the present studies kodecytes prepared using construct 49 were used as a 100% lysis control. A volume of 200 μL pooled AB serum and a volume of 100 μL kodecytes prepared using construct 49 at a concentration of 750 μg/mL was used as the 100% lysis control. A volume of 200 μL pooled AB serum and a volume of 100 μL O group RBCs (prepared as kodecytes without the addition of construct) was used as the 0% iysis control. To measure the ability of constructs to induce complement mediated autolysis of kodecytes volumes of 200 μL of pooled AB serum were dispensed into duplicate sets of test tubes. A volumes of 100 μL kodecytes was added to the tubes before incubation at 37° C. for 1 hour. Following incubation a volume of 1 μL ethylenediaminetetraacetic acid (EDTA) as its dipotassium salt
TABLE-US-00001 TABLE 1 Agglutination scores determined using samples of: naturally occurring Mia RBCs (“positive” control), kodecytes prepared using the construct 38 and its monomeric counterpart at the concentrations indicated, and unmodified RBCs (negative control). Concentration and construct used in the preparation of kodecytes Plasma 0.8% Trimeric MUT21 (38) Monomeric MUT21.sup.1 0.8% PCV sample Natural 0.01 mg/mL 0.03 mg/mL 0.03 mg/mL 0.01 mg/mL unmodified No. Mia RBCs 0.00098 mM/L 0.00293 mM/L 0.00879 mM/L 0.00293 mM/L RBCs 3 8 0 0 0 0 0 4 10 8 10 8 3 0 8 8 0 0 0 0 0 9 8 0 0 0 0 0 11 10 0 0 0 0 0 12 10 0 0 0 0 0 14 8 0 0 0 0 0 17 10 0 0 0 0 0 18 10 0 0 0 0 0 19 10 0 0 0 0 0 20 8 0 0 0 0 0 22 10 0 0 0 0 0 24 10 0 0 0 0 0 25 10 0 0 0 0 0 26 8 0 0 0 0 0 27 8 0 0 0 0 0 29 10 0 0 0 0 0 32 10 3 5 0 0 0 33 8 0 0 0 0 0 34 8 5 8 8 0 0 35 10 0 0 0 0 0 36 12 8 8 3 0 0 .sup.1the construct ‘monomeric MUT21’ was prepared according to the method disclosed in the publication of Bovin et al (2009) using construct 46.
TABLE-US-00002 TABLE 2 Construct used in the preparation of kodecytes and the observed degree of cell lysis (qualitative). Construct Degree of lysis 49 Partial 35 (0.66 μM) Complete 35 (0.33 μM) Complete 47 Partial 48 Complete 100% lysis control Complete 0% lysis control None
TABLE-US-00003 TABLE 3 Construct used in the preparation of kodecytes, absorbance (abs, 540 nm) measured for duplicate samples, percentage of cells lysed relative to 100% control and calculated percentage of cells lysed using standard curve. Construct Abs 1 Abs 2 (A1 and A2) Measured % Calculated % 49 .178 .187 .183 Set as 100 51 30 (0.66 μM) .351 .358 .355 194 97 30 (0.33 μM) .358 .326 .342 187 93 47 .224 .243 .234 128 65 48 .349 .345 .347 190 95 100% lysis .303 .310 .307 Not 85 control applicable 0% lysis .027 .005 .016 Not 7 control applicable
was added to each to each test tube to provide a final concentration of 0.1 mM EDTA. The test tubes were then centrifuged and the characteristics of the sedimented RBCs and supernatant observed (Table 2 and
[0139] Kodecytes prepared using the multivalent ligand construct 35 appear to be approximately twice as sensitive to autolysis as kodecytes prepared using the construct 49. The half molar and molar equivalents produced approximately equal degress of cell lysis. Kodecytes prepared using the construct 47 were somewhat more sensitive to lysis than kodecytes prepared using the construct designated 49. (This observation is consistent with the observations for antibody induced agglutination with kodecytes prepared using construct 38.) Kodecytes prepared using the construct 48 appear to be approximately twice as sensitive to lysis as kodecytes prepared using the construct 49. These observations are submitted to be predictive of the efficacy of the constructs when employed in the method of treating patients with tumours as disclosed in the publication of Galili et al (2015).
[0140] Although the invention has been described with reference to embodiments or examples it should be appreciated that variations and modifications may be made to these embodiments or examples without departing from the scope of the invention. For example, it is anticipated that bis(N-hydroxysuccinimidyl) succinate, bis(N-hydroxysuccinimidyl) glutarate, bis(N-hydroxysuccinimidyl) pimelate and bis(N-hydroxysuccinimidyl) suberate may each be substituted for the use of bis(N-hydroxysuccinimidyl) adipate (21) in the preparation of the compounds 23 and 34.
[0141] Where known equivalents exist to specific elements, features or integers, such equivalents are incorporated as if specifically referred to in this specification. For example, the preparation of 3-aminopropylglycosides other than those specifically described in here are disclosed in the publications of Audibert et al (1987), Bovin et al (1993), Galαnina et al (1997), Karelin et al (2010), Korchagina and Bovin (1992), Korchagina et al (2009), Krylov et al (2007), Nifant' ev et al (1996), Pazynina et al (2003), Pazynina et al (2014), Ryzhov et al (2012), Sherman et al (2001), Vodovozova et al (2000) and Yashunsky et al (2016). In particular, variations and modifications to the embodiments or examples that include elements, features or integers disclosed in and selected from the referenced publications are within the scope of the invention unless specifically disclaimed. It is anticipated that the 3-aminopropylglycosides disclosed elsewhere may be substituted for the compounds 29 and 33 in the synthetic schemes described here.
[0142] The advantages provided by the invention and discussed in the description may be provided in the alternative or in combination in these different embodiments of the invention.
REFERENCED PUBLICATIONS
[0143] Audibert et al (1987) Conjugates of haptenes and muramyl-peptides, endowed with immunogenic activity and compositions containing them U.S. Pat. No, 4,639,512,
[0144] Barr et al (2014) Mapping the fine specificity of ABO monoclonal reagents with A and B type-specific FSL constructs in kodecytes and inkjet printed on paper Transfusion, 54, 2477-2484.
[0145] Barr et al (2015) Monoclonal anti-A activity against the FORS1 (Forssman) antigen Transfusion, 55, 129-136.
[0146] Blake et al (2011) FSL constructs: a simple method for modifying cell/virion surfaces with a range of biological markers without affecting their viability J. Vis. Exp., 54, e3289; DOI: 10.3791/3289.
[0147] Bovin et al (1993) Synthesis of polymeric neoglycoconjugates based on N-substituted polyacrylamides Glycoconjugate Journal 10, 142-151.
[0148] Bovin et al (2005) Synthetic membrane anchors International application no. PCT/NZ2005/000052 (publ. no. WO 2005/090368).
[0149] Bovin et al (2009) Functional lipid constructs International application no. PCT/NZ2008/000266 (publ. no. WO 2009/048343).
[0150] Bovin et al (2010) Multiligand constructs International application no. PCT/EA2008/000006 (publ. no. WO 2010/043230).
[0151] Carter et al (2006) Cell Surface Coating with Hyaluronic Acid Oligomer Derivative US Patent WO/2007/035116.
[0152] Carter et al (2007) Cell Surface Coating with Hyaluronic Acid Oligomer Derivative International application no. PCT/NZ2006/000245 [publ. no. WO 2007/035116].
[0153] Frame et al (2007) Synthetic glycolipid modification of red blood cell membranes Transfusion, 47, 676-882.
[0154] Galanina et al (1997) Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutin with immunomodulatory potency Journal of Molecular Recognition, 10, 139-147.
[0155] Galili et al (2015) Glycolipid containing compositions for use in the treatment of tumours International application no. PCT/G 2015/051368 [publ. no. WO 2015/170121].
[0156] Georgakopoulos et al (2012) An improved Fc function assay utilizing CMV antigen coated red blood cells generated with synthetic function-spacer-lipid constructs Vox Sanguinis, 102, 72-78.
[0157] Harrison et al (2010) A synthetic globotriaosylceramide analogue inhibits HIV-1 infection in vitro by two mechanisms Glycoconj. J., 27, 515-524.
[0158] Henry (2009) Modification of red blood cells for laboratory quality control use Curr. Opin. Hematol., 16, 467-472.
[0159] Henry and Komarraju (2012) Peptide-lipid constructs and their use in a Fc-function assay International application no. PCT/2012/000029 (publ. no. WO 2012/118388).
[0160] Hult et al (2012) Flow cytometry evaluation of red blood cells mimicking naturally occurring ABO subgroups following modification with variable amounts of FSL_A and B constructs Transfusion, 52, 247-251.
[0161] Karelin et al (2010) Synthesis of 3,6-branched oligomannoside fragments of the mannan from Candida albicans cell wall corresponding to the antigenic factor 4 Carbohydrate Research 345, 1283-1290.
[0162] Korchagina and Henry (2015) Synthetic glycolipid-like constructs as tools for glycobiology research, diagnostics, and as potential therapeutics Biochemistry (Moscow), Vol. 80, No 7, 857-871.
[0163] Korchagina et al. (2009) Block synthesis of blood group tetrasaccharides B(types 1,3 and 4) Mendeleev Commun., 19, 152-154.
[0164] Korchagina et al (2012) Toward creating cell membrane glycolandscapes with glycan lipid constructs Carbohydr. Res., 356, 238-246.
[0165] Lee and Lee (1.997) Facile Synthesis of a High-Affinity Ligand for Mammalian Hepatic Lectin Containing Three Terminal N-Acetylgalactosamine Residues Bioconjugate Chem., 8, 762-765.
[0166] Litherland and Mann (1938) The amino-derivatives of pentaerythritol Part I. Preparation Journal of the Chemical Society, 1588-95.
[0167] McNaught (1996) Nomenclature of carbohydrates Pure & App. Chem., 68, No. 10, 1919-2008.
[0168] Nifant' ev et al (1996) Selectin-receptors 4: synthesis of tetrasaccharides sialyl Lewis A and sialyl Lewis X containing a spacer group.sup.1,2 J. Carbohydrate Chemistry, 15(8), 939-953.
[0169] Oliver et al (2011) In vivo neutralization of anti-A and successful transfusion of A antigen incompatible red cells in an animal model Transfusion, 51, 2664-2675.
[0170] Oliver et al (2011) Modeling transfusion reactions and predicting in vivo cell survival with kodecytes Transfusion, 51, 1723-1730.
[0171] Paulsen et al (1978) Darstellung selektiv blockierter 2-azido-2-desoxy-.sub.d-gluco-und-.sub.d-galactophyranosylnalogenide: Reaktivitat und .sup.13C-NMR-Spektren Carbohydrate Research, 64, 339-364.
[0172] Pazynina et al (2003) Synthesis of complex 2-3 sialooligosaccharides, including sulfated and fu cos via ted ones, using Neu5Acα2-3Gal as a building block Mendeleev Commun, 13(6), 245-248.
[0173] Pazynina et al (2008) The synthesis of linear trilactosamine Russian Journal of Bioorganic Chemistry, Vol. 34, No. 5, 625-631.
[0174] Perry and. Henry (2013) Teaching the recognition of hemolysis by controlling antibody mediated in vitro hemolysis with kodecytes Transfusion, 53 (Suppl. ), 182A.
[0175] Perry and Henry (2015) Training students in serologic reaction grading increased perceptions of self-efficacy and ability to recognize serologic reactions but decreased grading accuracy Transfusion, Jan. 7, DOI: 10.1111/trf.12985 [Epub ahead of print].
[0176] Rhyzhov et al (2012) Block synthesis of A tetrasaccharides (types 1, 3 and 4) related to the human ABO blood group system Carbohydrate Research 351, 17-25.
[0177] Sherman et al (2001) Synthesis of Neu5Ac-and Neu5Gc-α-(2.fwdarw.6′)-lactosamine 3-aminopropyl glycosides Carbohydrate research 330, 445-458.
[0178] Svensson et al (2013) Forssman expression on human erythrocytes: biochemical and genetic evidence of a new histo-blood group system Blood, 121, 1459-1468.
[0179] Vodovozova et al (2000) Antitumour activity of cytotoxic liposomes equipped with s electin ligand SiaLe.sub.x, in a mouse mammary adenocarcinoma model European Journal of Cancer, 36, 942-949.
[0180] Yashunsky et al (2016) Synthesis of 3-aminopropyl glycosides of linearβ-(1.fwdarw.3)-D-glucooligosaccharides Carbohydrate Research 419, 1-10.